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The word hematopoiesis is derived from the greek words, haima meaning blood and poiesis 
meaning to make. Hematopoiesis is a tightly regulated process which ensures production of 
appropriate amounts of different blood cell types. All blood cell types are derived from plu-
ripotent hematopoietic stem cells (HSCs). The HSCs are capable of self renewal. Committed 
myeloid progenitor cells are derived from the HSCs. Committed myeloid progenitor cells are 
able to proliferate and differentiate into mature blood cells like, granulocytes (neutrophils, 
eosinophils, basophils), lymphocytes, erythrocytes, platelets, macrophages, natural killer 
cells, dendritic cells and mast cells. During embryogenesis HSCs develop in the aorta-gonad-
mesonephros (AGM) region [1-3]. HSCs migrate to the fetal liver which is the main site of 
hematopoiesis until birth [4]. After birth, the bone marrow takes over as the primary site of 
hematopoiesis. 
The process of hematopoiesis is largely dependent on the hematopoietic growth factors 
(HGFs). HGFs control proliferation and survival by activation of their respective receptors. 
Some HGFs also induce differentiation of cells. Major HGFs are erythropoietin (Epo), re-
sponsible for erythropoiesis; interleukins (IL’s), involved in all lineages; colony-stimulating 
factors (CSFs) which are involved in myeloid cell development; thrombopoietin (TPO) in-
volved in stem cells and megakaryocytic development; stem cell factor (SCF) and Flt3 which 
are growth factors for pluripotent stem cells [5]. The family of CSFs includes granulocyte-CSF 
(G-CSF), granulocyte- macrophage-CSF (GM-CSF), multipotential-CSF (multi-CSF or IL-3) 
and macrophage- CSF (CSF-1) [6-9]. 
Unlike other HGFs, G-CSF plays an important role not only in proliferation of early 
progenitor cells but also in induction of differentiation [9-11]. G-CSF regulates both, pro-
liferation of myeloid progenitor cells as well as differentiation of myeloid progenitor cells 
into neutrophils [12-15]. Neutrophils have a limited life span of approximately 5.4 days [16]. 
They can ingest and kill microbes by phagocytosis. Each phagocytotic event results in the 
formation of a phagosome into which reactive oxygen species (ROS) and hydrolytic enzymes 
to kill the pathogens are released [17-18]. The rapid release of ROS into the phagosomes has 
been termed as the “respiratory burst”. In the process of killing of microbes, the neutrophils 
die. It is important to maintain neutrophil levels as they form a barrier against infection. On 
an average about 50 million neutrophils are produced per minute in adults [5]. 
1.2.  GRaNuLOCyTE COLONy STIMuLaTING faCTOR (G-CSf)
G-CSF is a member of the cytokine class I superfamily [19]. The best documented role of 
G-CSF is to maintain steady state levels of neutrophils in vivo by inducing differentiation 
of myeloid progenitor cells to form neutrophils [12-15, 20]. In mature neutrophils, G-CSF 
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enhances neutrophil effector functions like superoxide generation, production of leukocyte 
alkaline phosphatase, myeloperoxidase and release of arachidonic acid [21-23]. G-CSF 
deficient mice (csf3-/-) develop a severe neutropenia with blood neutrophil levels ranging 
from 15- 30% of wild type littermate controls [14]. These mice are especially susceptible to 
bacterial infections like Listeria monocytogenes.  This is due to their inability to rapidly elevate 
neutrophil levels, a process known as ‘emergency granulopoiesis’, the second major function 
of G-CSF. 
Because of its ability to induce neutrophil production, G-CSF is commonly used in 
treatment of severe congenital neutropenia (SCN), leukemia and anaemia. Administration 
of G-CSF to neutropenia patients, who have severely reduced neutrophil levels due to a 
block in myeloid differentiation, induces neutrophil production which helps in reducing the 
risk of bacterial infections [24-26]. Another important clinical application of G-CSF is for 
transplantation purposes, wherein G-CSF induces the release of hematopoietic stem cells and 
progenitor cells from the bone marrow into the peripheral blood, an important fraction of 
blood cells which is required for successful transplantations [27].
1.3  GRaNuLOCyTE COLONy STIMuLaTING faCTOR RECEPTOR (G-CSfR)
The effects of G-CSF are mediated via the G-CSFR. G-CSFR is also known as CSF3R and 
lacks intrinsic tyrosine kinase activity. G-CSFR is a transmembrane protein consisting of 
813 amino acids with 603 amino acids being part of an extracellular domain [28-29]. The 
extracellular portion consists of an Immunoglobulin-like (Ig-like) domain, a cytokine recep-
tor homology domain (CRH domain) and three fibronectin type III (FN III) modules. The 
CRH domain contains four highly conserved cysteine residues and a WSXWS motif that is 
required for ligand binding. 
The cytoplasmic domain of the G-CSFR consists of box 1, box 2 and box 3 regions, in-
volved either in transduction of proliferation signals (box 1 and box 2) or to be essential for 
ligand induced differentiation signals of myeloid progenitor cells (box 3) [30-32]. Besides the 
box regions, signaling from the G-CSFR is dependent on tyrosines (Y) and lysines (K) pres-
ent in the cytoplasmic tail of the G-CSFR. The cytoplasmic tail contains four tyrosine residues 
located at positions 704, 729, 744 and 764. Upon activation of receptor, these tyrosines are 
phosphorylated and serve as docking sites for Src homology 2 (SH2) domain containing sig-
naling proteins. Five conserved lysines at positions 632, 672, 681, 682 and 762 are also present 
in the cytoplasmic domain of G-CSFR. Both, the most membrane proximal lysine, K632, and 
the tyrosine, Y729, play a key role in ubiquitination and lysosomal routing of G-CSFR, as is 
discussed in section 1.5.2 [33-34]. A balance between phosphorylation and dephosphoryla-
tion of tyrosines and the ubiquitination status of lysines of the receptor ensures a regulated 
signaling response and routing of the G-CSFR
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1.4  G-CSfR SIGNaL TRaNSduCTION
Activation of the G-CSFR leads to activation of several downstream signaling pathways in-
cluding the Janus tyrosine kinases (Jak) and Signal transducer and activators of transcription 
(Stat) pathway, phosphatidyl ionositol-3 kinase (PI3K) pathway and the p21Ras/Raf/ mito-
gen activated protein kinase of Erk kinase (MEK) /mitogen activated protein kinase (MAPK) 
pathways (Figure 1). The mechanisms of activation of these pathways and their implications 
for G-CSFR signaling have been discussed below.
 
  
figure 1: G-CSfR signaling
Activation of G-CSFR signaling is characterised by phosphorylation of tyrosines of the G-CSFR by Jaks. The phos-
phorylated tyrosines then act as docking sites for other molecules which either positively or negatively regulate 
signaling via the G-CSFR.
Figure 1
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1.4.1  The Jak /Stat pathways
The G-CSFR lacks intrinsic tyrosine kinase activity and relies on the Janus tyrosine kinases 
(Jak) family for signal transduction. Activation of the G-CSFR leads to activation of 3 members 
of the Jak family, namely, Jak1, Jak2 and Tyk2 [35-39]. Phosphorylation-mediated-activation 
of Jak1, Jak2 and Tyk2 upon stimulation with G-CSF is dependent on tryptophan (W) 650 
of the G-CSFR [37, 40]. Activated Jaks not only phosphorylate tyrosines of the G-CSFR but 
also those of Stat proteins. Phosphorylation of Stat proteins results in their homo/ heterodi-
merization [41]. The dimerized Stat molecules translocate to the nucleus where they activate 
transcription of target genes. 
Upon stimulation with G-CSF, 2 members of the Stat family, Stat3 and Stat5 are activated. 
The role of Stat3 in negative regulation of G-CSFR signaling was elucidated in mice lacking 
Stat3 expression in hematopoietic progenitors. These mice developed neutrophilia due to hy-
per responsiveness to G-CSF because they fail to induce expression of suppressor of cytokine 
signaling 3 (SOCS3), a direct Stat3 target gene (see section 1.5.2) [42]. The activation of Stat3 
occurs via its recruitment to phosphorylated Y704 and Y744 of the G-CSFR [43-44] (Figure 
1). Stat3 plays a role in cell cycle exit by inducing expression of the cyclin dependent kinase 
(CDK) inhibitor, p27Kip1 [45]. Stat3 binding sites have been identified in the p27Kip1 promoter 
region. Introduction of a dominant negative form of Stat3 interferes with growth arrest and 
differentiation of 32D myeloid progenitor cells [45-46] mainly due to inhibition of p27Kip1 
expression upon G-CSF stimulation. 
Unlike Stat3, Stat5 is not recruited directly to the tyrosines of G-CSFR. Its activation 
occurs by interaction with the activated Jaks [47]. Stat3 and Stat5 differ in their activation 
kinetics in response to G-CSF. While Stat3 activation by G-CSF is sustained for hours, Stat5 
activation is transient and is reduced to basal levels 30 minutes after stimulation with G-CSF 
[48]. Stat5 is responsible for propagation of proliferation and survival signals via the G-CSFR 
[49]. In accordance with this, mice lacking both the isoforms of Stat5 show reduced colony 
forming capacity in response to G-CSF [50]. BA/F3 cells expressing a lysine-less G-CSFR 
show prolonged Stat5 activation indicating a role of ubiquitination of G-CSFR in Stat5 signal 
down regulation [34]. 
1.4.2   PI3K and RaS pathways
Phosphotidylinositol-3 kinase (PI3K) enzymes are a family of lipid kinases consisting of three 
distinct subclasses based on their structure and substrate specificity [51]. Phosphotidylino-
sitol 4, 5 bisphosphate {PI(4,5)P2} or PIP2 is the most common substrate for the PI3K class I 
members. PIP2 can be phosphorylated upon extracellular stimuli to form phosphotidylinosi-
tol 3, 4, 5 trisphosphate {PI(3,4,5)P3} or PIP3 [52]. The PIP3 thus generated acts as a docking 
site for pleckstrin homology (PH) domain- containing proteins like protein kinase B (PKB/ 
c-AKT) [53]. 
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The membrane proximal region of the G-CSFR is involved in activation of the PI3K/ PKB 
pathway [54]. The activation of PI3K pathway is dependant on c-Src activation, rather than 
Jak activation but this may be cell context dependent [54]. PI3K activation results in phos-
phorylation mediated activation of PKB. Myeloid 32D cells expressing the internalization 
defective ∆715-G-CSFR mutant show prolonged PKB activation due to increased activation 
of the upstream PI3K [54]. G-CSF induced activation of PI3K/ PKB pathway leads to in-
creased cell survival brought about by inducing a block in apoptotic cascades. Pro-apoptotic 
protein Bad is activated by PKB. However the phosphorylated Bad is sequestered by 14-3-3 in 
the cytosol. This inhibits interaction between Bad and anti-apoptotic Bcl2 and Bcl-xl proteins 
resulting in increased cell survival [54-55]. 
Activation of the p21Ras/Raf/MEK/MAPK pathway via the G-CSFR is linked to the 
phosphorylation of Y764 of the G-CSFR [56-57]. Phosphorylated Y764 acts as a docking site 
for the SH2 domains of Shc and Grb2, the signaling intermediates of the p21Ras pathway [57-
59]. Introduction of the Y764F-G-CSFR mutant results in reduced activation of the p21Ras 
pathway and accelerated neutrophil differentiation [57]. 
1.5    NEGaTIvE REGuLaTION Of G-CSfR SIGNaLING
Cytokine mediated activation of signaling is usually transient. Several negative regulatory 
pathways are responsible for switching-off signaling. Major mechanisms involved in signal 
attenuation are internalization of receptors, lysosomal degradation triggered by ubiquitina-
tion of proteins, Janus kinase inhibitory action of SOCS proteins and dephosphorylation of 
proteins by phosphatases. These mechanisms will be introduced below.
1.5.1   Trafficking of activated G-CSf receptors
Endocytosis of receptors involves internalization of receptors from the plasma membrane, 
trafficking to early endosomes, late endosomes, multi-vesicular bodies (MVBs) and then to 
lysosomes, where the receptors are degraded. Receptor internalization can occur either via 
clathrin-coated pits or via caveolae. The G-CSFR is known to undergo endocytosis via clath-
rin-coated pits [60]. A region of the G-CSFR that contains the dileucine motif (a.a 749-769) 
is essential for both ligand-induced and constitutive internalization. Besides the dileucine 
motif, the presence of tryptophan (W650, involved in Jak activation) and phosphorylation of 
serine (S749) are critical for ligand-induced internalization [60]. 
Upon internalization, the endocytosed G-CSFR vesicles form early endosomes. Early 
endosomes are considered to be sorting vesicles in which the fate of the internalized recep-
tors is controlled. The receptors are sorted based on the ubiquitination of the lysines in the 
cytoplasmic tail. Ubiquitination of G-CSFR occurs via the SOCS box of SOCS3. The role 
SOCS3 plays in down modulation of G-CSFR signaling will be explained in section 1.5.2. 
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Receptors that have been ubiquitinated are targeted for degradation and further route to late 
endosomes/ lysosomes [61]. 
Fusion of early endosomes leads to the formation of late endosomes. Internalization of 
activated receptors and their routing to early endosomes occurs independent of ubiquitina-
tion of the G-CSFR [33-34]. However, the post-endocytotic routing of the G-CSFR to lyso-
somes is dependent on SOCS3-mediated ubiquitination of membrane proximal lysine, K632 
of the G-CSFR [33-34]. By invaginations of the membrane of the late endosomes into its 
lumen are formed the multivesicular bodies (MVBs). The ESCRT (endosomal sorting com-
plexes required for transport) machinery mediates efficient transport of the receptors into 
the MVB pathway [62]. The ESCRT complex interacts with the ubiquitinated receptors via 
the ubiquitin binding domains (UBDs) present in the proteins of the ESCRT complex [63]. 
Eventually the ubiquitinated receptors are de-ubiquitinated by de-ubiquitinating enzymes 
(DUBs) [63-65]. Finally the MVBs with the sorted and de-ubiquitinated receptors fuse with 
the lysosomes where the receptors are degraded. The lysosomes have an acidic pH (4.8) and 
degradative enzymes which are responsible for degradation of the receptor cargo.
1.5.2 ubiquitination via SOCS3
In receptor-mediated signaling, a negative feedback loop exists as expression of SOCS3 is 
under direct control of Stat3 [66-69]. G-CSF stimulation is known to induce expression of 
SOCS3 [70-71]. Stat3-/- mice show reduced levels of SOCS3 expression upon stimulation 
with G-CSF, which suggests that SOCS3 is a target of Stat3 in G-CSF signaling [42]. In bone 
marrow cells, Stat3 is required for robust induction of SOCS3 in response to G-CSF stimula-
tion [42, 48, 70]. SOCS3 is subsequently recruited to Y729 of the G-CSFR [70]. 
SOCS3 knock-out mice were shown to be embryonic lethal due to placental function 
defects [72-73]. Studies in SOCS3 conditional knockout mice have shown that SOCS3 is 
also a major negative regulator of G-CSF dependent neutrophil production. These mice 
demonstrate neutrophil leukocytosis after they reach adulthood and show infiltration of 
hematopoietic cells into various tissues [74-75]. When stimulated with G-CSF in vitro, the 
SOCS3 deficient cells exhibited prolonged Stat3 activation and enhanced cellular responses 
to G-CSF, including an increase in colony formation and proliferation. Consistent with 
the in vitro findings, SOCS3 mutant mice administrated with G-CSF displayed enhanced 
neutrophilia, indicating that loss of SOCS3 results in hypersensitivity towards G-CSF [74]. 
SOCS3 has been shown to inhibit G-CSF mediated signaling by different mechanisms. 
The first mechanism by which SOCS3 down regulates G-CSF signaling is by ubiquitination 
of the membrane proximal lysine K632 [33]. Although all the five lysines in cytoplasmic 
tail of G-CSFR are ubiquitinated, routing of G-CSFR from early endosomes to lysosomes is 
dependent on the ubiquitination of K632 by SOCS3 [33]. Loss of the SOCS3 recruitment site 
(Y729) of the G-CSFR, leads to decreased ubiquitination of the G-CSFR mutant in which 
K632 is the only lysine in its cytoplasmic tail. 
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In addition to the SH2 domain and the carboxy terminal SOCS box possessed by all of 
the SOCS family members, SOCS3 also possesses a kinase inhibitory region (KIR) [76-77]. 
The second mechanism, shown for other receptors is by inhibition of Jak activity via the KIR 
of SOCS3 bound to Y729 of G-CSFR [78-80]. Another mechanism by which SOCS3 inhibits 
cytokine receptor activation is by competing with Stat3 for binding the phosphorylated tyro-
sines of the G-CSFR; a process which is essential for activation for Stat3 [81-82].
1.5.3  de-phosphorylation via phosphatases
The human genome encodes for about 107 different protein phosphatases which recognize 
and remove phosphate moieties attached to tyrosine/ threonine/ serine from proteins. The 
PTP family consists of classical PTPs that dephosphorylate only tyrosine residues (pTyr) and 
dual specificity phosphatase (DUSPs) which dephosphorylate pSer, pThr and pTyr residues 
[83-85]. The PTPs which dephosphorylate tyrosines consist of two types, receptor protein 
tyrosine phosphatases (RPTPs) and non-transmembrane, cytoplasmic PTPs [86]. Oxidation 
of the catalytic cysteine residue of phosphatases renders the phosphatases inactive. However 
this process is reversible and antioxidants can recycle the oxidized inactive phosphatases 
to their active forms. The mechanism of oxidative inactivation of phosphatases and their 
reactivation by antioxidants will be discussed in detail in section 1.7.2 of this chapter. The role 
of some PTPs known to regulate G-CSF mediated signaling is discussed below.
- Shp1
The non-transmembrane protein tyrosine phosphatase, Shp1 (also known as Ptpn6), is ex-
pressed mostly in hematopoeitic cells and affects G-CSFR signaling [87-89]. Shp1 is mainly 
a cytosolic protein which translocates to the receptors at the plasma membrane upon activa-
tion [90]. Fractions of Shp1 have also been detected in the nucleus [91]. Mice carrying a loss 
of function mutation in the Shp1 gene display myeloid as well as lymphoid abnormalities. 
Interaction of Shp1 with G-CSFR occurs independently of cytoplasmic tyrosines of the G-
CSFR [92-94]. Protein levels of Shp1 are increased during G-CSF induced differentiation in 
32D cells. While the overexpression of Shp1 in 32D cells inhibits proliferation and stimulates 
differentiation, the overexpression of a catalytically inactive Shp1 results in inhibition of dif-
ferentiation and stimulation of proliferation in 32D cells [94]. Overexpression of Shp1 in 32D 
cells results in slightly decreased p-Stat5 levels while overexpression of catalytically inactive 
Shp1 mutant results in increased Stat5 activation [94].
- Shp2
Shp2, alternatively known as Ptpn11, has also been implicated in G-CSFR signal down 
regulation. Shp2, like Shp1, is predominantly a cytosolic protein which translocates to acti-
vated receptors at the plasma membrane [90]. Shp2 competes with SOCS3 for binding to the 
phosphorylated tyrosine Y729 of the G-CSFR [48]. However another C-terminal region of 
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the G-CSFR is also important for the interaction of Shp2 with G-CSFR [48]. Shp2 also binds 
to Y704 and Y764 of the G-CSFR along with Grb2 and/or Shc [59]. Because the tyrosines 
704 and 764 are strongly involved in propagation of proliferation signals via G-CSFR, it is 
thought that Shp2, Grb2 and Shc mediate these responses. One of the proposed functions 
of Shp2 in G-CSFR signal regulation is dephosphorylation of Stat5 [95]. In the context of 
the epidermal growth factor receptor (EGFR), Shp2 prolongs Ras activation (GTP-Ras) [96]. 
Shp2 dephosphorylates the tyrosine (Y992) of the EGFR which acts as the docking site for the 
Ras GTPase activating protein (Ras-GAP). This leads to inability of Ras-GAP to translocate to 
the same micro domain as its substrate, GTP-Ras, thereby leading to increased levels of GTP-
Ras. Whether Shp2 regulates GTP-Ras signaling in response to G-CSF remains unknown.
- ShIP1
Tyrosine, Y764 present in the C-terminal of the G-CSFR is required for activation of yet 
another cytosolic phosphatase, SHIP1 and for the formation of Shc/SHIP complexes [49, 
97-98]. SHIP1 is a 5’-phosphatidylinositol (PtdIns) phosphatase that de-phosphorylates 
PIP3 at the 5 position. Numbers of neutrophils and monocytes/ macrophages are increased 
in SHIP1-/- mice [99-100]. Furthermore, neutrophils derived from SHIP1-/- mice show 
prolonged survival in response to apoptotic stimuli or to growth factor withdrawal [100]. 
Defects in hematopoietic signaling, particularly in the myeloid lineage have been observed in 
SHIP-deficient mice [99].  
- Ptp1b
Protein tyrosine phosphatase 1b (Ptp1b) is localized to the ER with its C-terminal hydro-
phobic sequence anchored to the cytoplasmic face of the ER and a short tail extending into 
the lumen of the ER [101-102]. Ptp1b-/- mice are hypersensitive to insulin as well as leptin 
[103-105]. Ptp1b is known to modulate metabolic signaling in mammals [103, 106-107]. One 
of the important mechanisms by which Ptp1b negatively regulates signaling via EGFR, plate-
let derived growth factor receptor (PDGFR), insulin receptor and erythropoietin receptor 
(EPOR) is by dephosphorylation of tyrosines of the receptors [108-110]. Besides dephos-
phorylation of the tyrosines of several receptors, Ptp1b was shown to physically interact with 
Jak2 and negatively regulate the activity of both Jak2 and Stat3 in case of the leptin receptor 
signaling [105, 111] and Stat6 in case of interleukin 4 (IL-4Rα) signaling [112]. MEFs and 
splenocytes lacking Ptp1b expression also showed increased ROS levels in response to IL-4 
stimulation as compared to wild type controls. 
Although the role of Ptp1b in negative regulation of signaling via RTKs and cytokine 
receptors is clear, how could an endoplasmic reticulum (ER) localized phosphatase nega-
tively regulate signaling from activated receptors. However, data from Haj et al showed that 
activated EGFRs routed via the ER where the receptors were dephosphorylated by Ptp1b 
when the EGFR-containing early endosomal vesicles were in the vicinity of the ER [113]. 
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More recent findings show that the interaction between Ptp1b and EGFRs occurs via direct 
membrane contacts between the outer membrane of the multivesicular bodies (MVBs), 
containing endocytosed EGFR vesicles and the endoplasmic reticulum, onto which is present 
Ptp1b [114]. Loss of Ptp1b leads to decreased formation of internal vesicles within the MVB 
suggesting that the dephosphorylation of EGFRs occurs prior to their internalization within 
the MVBs and that dephosphorylation is essential for routing to MVBs [114]. 
Ptp1b is also thought to regulate the endocytotic pathway. This was proposed based on 
the findings that Ptp1b dephosphorylates STAM2, a member of the ESCRT complex, thereby 
increasing its affinity for binding ubiquitinated proteins resulting in lysosomal degradation 
of EGFR [115-116]. Taken together, it is evident that Ptp1b plays a key role in negative regu-
lation of receptor signaling. Whether Ptp1b down modulates G-CSFR mediated signaling 
and its routing has not been examined so far.
attenuation of G-CSfR mediated signal transduction likely involves dephos-
phorylation of G-CSfR tyrosines. Ptp1b has been shown to be essential for 
dephosphorylation of tyrosines of activated receptors and also attenuation of 
downstream signaling initiated by activated receptors. 
we examined whether Ptp1b played a role in down modulation of signaling 
and proliferation in response to G-CSf. This could be either by means of 
dephosphorylation of tyrosines of G-CSfR and/or by means of dephosphory-
lation of other downstream signaling molecules involved in G-CSfR signal 
transduction.
These questions have been addressed in Chapter 2 of this thesis.
1.6 abNORMaL G-CSf SIGNaLING IN MyELOId dISORdERS
Acute myeloid leukemia (AML) is characterised by accumulation of blasts in the bone mar-
row due to a block in differentiation and enhanced proliferation and survival of myeloid 
progenitor cells. As mentioned before, G-CSF is known to induce differentiation of myeloid 
progenitor cells to neutrophils. However administration of G-CSF to blasts from AML pa-
tients leads to enhanced proliferation of blasts and marginal/ no differentiation [117]. This 
difference in response to G-CSF has been linked to the increased expression of a different 
isoform of the G-CSFR (Class IV) as compared to normal immature myeloid cells which 
express Class I isoform [118]. The Class IV isoform of the G-CSFR was shown to be defective 
in differentiation [119]. 
A novel splice variant of G-CSFR was described by Awaya and colleagues [120]. This 
splice variant results in deletion of three nucleotides in the juxtamembrane region of the 
G-CSFR resulting in the conversion of aspargine and arginine (N630 R631) residues to lysine 
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(K630). Although the splice variant was also detected in normal bone marrow cells with a 
frequency of 2%, it was found at an increased frequency of 8% in myeloid progenitor cells in 
myelodysplastic syndrome (MDS). This modification in the juxtamembrane region leads to 
increased proliferation in response to G-CSF compared to the wild type G-CSFR. However 
the role of this modification in MDS remains unknown.
Another polymorphism in the G-CSFR distal carboxyl region leading to the conversion of 
glutamic acid (E785) to lysine (K785) has been associated with high risk MDS patients [121]. 
Expression of this variant in myeloid progenitor cells leads to decreased proliferation of pro-
genitor cells compared to the wild type controls. This finding can be explained based on the 
established role of lysines in ubiquitination mediated proteasomal degradation of substrates.
A sub class of leukemia, acute promyelocytic leukemia (APL) characterised by t(15;17) is 
hyper proliferative in response to G-CSF treatment [122]. In case of cells derived from APLs, 
G-CSF is unable to induce differentiation indicative of defects in signaling via the G-CSFR.
Mutations in G-CSFR are rare in de-novo AMLs and myelodysplasia (MDS). In contrast, 
mutations in G-CSFR commonly occur in patients with severe congenital neutropenia (SCN) 
[123]. Most frequently occurring mutations in the G-CSFR in SCN patients are nonsense 
mutations introducing stop codons in the cytoplasmic domain of the G-CSFR [123-124]. 
Expression of truncated forms of the G-CSFR in SCN patients is commonly associated with 
progression towards development of AML [123-125]. 
Expression of the mutant G-CSFR (∆715-G-CSFR) in mice results in hyper proliferation 
in response to G-CSF [126-127]. Signaling via the ∆715-G-CSFR (PI3K/PKB and p-Stat5) 
is prolonged as compared to the wt-G-CSFR due to loss of binding sites of the negative 
inhibitory molecules like SOCS3, SHIP1 and Shp1 [33, 49, 92, 94, 128]. Internalization of 
the ∆715-G-CSFR is also affected because of loss of internalization motifs present in the C-
terminal region [60]. Expression of the ∆715–G-CSFR truncation mutant in 32D cells results 
in an increased production of reactive oxygen species (ROS) upon stimulation with G-CSF as 
compared to wt-G-CSFR expressing cells [129]. 
1.7 REdOx SIGNaLING
Redox signaling is the process in which free radicals or ROS act as messengers in biological 
systems. ROS are commonly produced as by-products of metabolism in cells. If produced 
in large amounts ROS are toxic to cells as they can induce damage to DNA, proteins, carbo-
hydrates and lipids [130-131]. ROS levels are deregulated in ageing and a variety of chronic 
diseases, such as cardiovascular diseases and cancer [132-135]. However, in small amounts 
ROS have been shown to have a major impact on cellular signaling. The importance of ROS 
mediated signaling and its regulation is discussed in the following sections.
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1.7.1  Production of reactive oxygen species
ROS have for long been considered to be unwanted by-products of metabolism in cells, 
with the exception of phagocytic cells of the immune system, in which ROS are produced 
in large amounts [136-137]. The high level of ROS (H2O2) produced in these short-lived 
cells acts as an oxidative burst which is a major weapon in host defence against bacteria. In 
non-phagocytic cells, ROS such as H2O2 or superoxide are generated by different pathways 
in cells mostly in the mitochondria and in the endoplasmic reticulum. Besides being the 
normal end-products of metabolism in cells, ROS are produced when cells are activated by 
extracellular stimuli. ROS act as second messengers which activate signaling pathways in 
cells by transient deregulation of the activity of redox sensitive enzymes, in particular protein 
tyrosine and lipid phosphatases [130]. The mechanism by which ROS regulate the activity of 
phosphatases has been discussed in section 1.7.2 of this chapter.
The NADPH (nicotinamide adenine dinucleotide phosphate) oxidase (Nox) system plays 
a major role in production of ROS. The Nox system is involved not only in ROS production 
upon receptor activation but also in the production of an oxidative burst in phagocytic cells. 
In phagocytic cells, the Nox system comprises of the membrane bound cytochrome b (b558) 
consisting of the gp91phox (also known as Nox2) and p22phox subunits. Generation of ROS 
by the catalytic Nox2 subunit requires the recruitment of the organiser p47phox, activator 
p67phox subunits and Rho guanosine triphosphatase (GTPase)-Rac1 [138-140]. In the non-
phagocytic cells homologs of Nox2- Nox1, Nox3, Nox4 and Nox5 have been identified [141]. 
These homologues of Nox2 require different subunits for their activation. 
Components of the Nox complex are localized within specific subcellular compartments. 
While Nox1 is localized within the nucleus and at the plasma membrane, specifically in the 
caveolae [142-143], Nox2 is detected on the plasma membrane but translocates to endosomes 
in IL-1 stimulated cells [144]. Under overexpression conditions, Nox3 was detected in the 
cytoplasm [145]. Nox4 is localized in the perinuclear regions, endoplasmic reticulum, at 
the plasma membrane and also within the mitochondria [146-148]. Under overexpression 
conditions, Nox5 was also detected at the plasma membrane [149-150]. The differential 
subcellular localization of the Nox subunits is important for the local production of ROS, 
necessary for signal transduction. 
The local role of the Nox sytem has been elucidated in the context of the interleukin-1 
receptor (IL-1R) [144]. It was demonstrated that Nox2 controls the binding of Traf6 to the 
IL-1R/MyD88 complex in early endosomes (Figure 2). Upon assembly of the Nox2 machin-
ery at the early endosomes at the IL-1R/MyD88 complex, ROS production occurred locally 
in the early endosome compartment [144]. The ROS produced locally diffused through the 
membrane of the endosomes and this led to recruitment of Traf6 to the IL-1R complex at the 
early endosomes. Also in case of the IL-4R, Nox1 and Nox5L were shown to be involved in 
ROS production [112]. 
 




figure 2: assembly of the Nox2 complex in early endosomes
Activation of IL-1 receptors leads to internalization of the IL-1 receptor along with membrane localized- Nox2, Rac1 
and Myd88. The assembly of the Nox complex occurs at the endosomes where IL-1 mediated production of ROS 
occurs. The ROS produced are capable of diffusing through the membrane of the endosomes and this brings about 
the recruitment of Traf6 to the IL-1-Nox2 complex. 
Activation of transmembrane receptors, such as platelet-derived growth factor receptor 
(PDGFR), interleukin 3 receptor (IL-3R) and granulocyte-macrophage colony-stimulating 
factor receptor (GM-CSFR), results in increased intracellular ROS levels which enhances 
the signaling function of these receptors, conceivably by down regulation of phosphatase 
activities [129, 151-153].Taking into account the toxic effects of ROS, the timely inactivation 
of Nox and also the maintenance of ROS levels produced are critical processes.
1.7.2 Oxidative inactivation of phosphatases
All phosphatases contain the amino acid cysteine in their catalytic site. The catalytic cysteines 
of phosphatases have a very low pKa [154]. The low pKa of the cysteine is necessary for the 
process of catalysis, whereby a phosphate group is accepted by the thiol group of the cysteine 
residue. But the low pKa also makes the cysteine extremely susceptible to undergo oxidative 
inactivation upon exposure to ROS [155-156]. ROS selectively inactivate tyrosine phospha-
tases while they have no effect on serine or threonine phosphatases [157]. 
Figure 2
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figure 3: Inactivation of phosphatases by ROS
The amino acid cysteine in the catalytic site of protein tyrosine phosphatases (PTPs) is especially sensitive to oxida-
tion by ROS. Upon oxidation, the thiol group is converted into a sulfenic acid derivative which renders the phos-
phatase inactive. The inactive phosphatase is then reactivated by peroxiredoxins by reduction of the sulfenic acid 
derivative to thiol group.
The amino acid cysteine consists of a thiol group (SH) in its side chain. Upon exposure 
to hydrogen peroxide, the hydroxyl group of hydrogen peroxide covalently interacts with 
the thiol side chain of the catalytic cysteine (Figure 3). This leads to formation of a sulfenic 
acid (S-OH) derivative which renders the phosphatase inactive [157]. The sulfenic stage of 
oxidation of phosphatases can be reversed by antioxidants leading to the formation of a thiol 
group thereby generating a catalytically active cysteine. However excessive oxidation of the 
thiol group could also occur leading to the formation of catalytically inactive sulfinic acid 
(SO2H) or sulphonic acid (SO3H) derivatives, which cannot be readily reversed back to their 
active forms.
Under physiological conditions, only reversible oxidation of PTP occurs. Several reports 
show oxidation of PTPs in response to various stimuli. For eg. Ptp1b oxidation has been 
reported in response to stimulation with EGF or insulin [155, 158-159]. It has been shown for 
the EGF receptor that the ROS production coincides with inhibition of Ptp1b activity [160]. 
Nox4 activation upon stimulation with IL4 also leads to inhibition of Ptp1b activity [112]. 
While TC-PTP was shown to be oxidized in response to insulin [159], Shp2 was shown to 
be oxidized in response to PDGF stimulation [156]. The sensitivity of each PTP to oxidation 
might depend on a couple of factors. Firstly, the structure of the catalytic domain of the PTP 
as well as its regulatory domain might influence its sensitivity to oxidation. Another key 
factor could be the relative distance of the PTP from the site of ROS generation
1.7.3 Role of antioxidants in signaling
Antioxidant enzymes protect the cells against the damaging effects of oxidants. Antioxidants 
play distinct roles in the different metabolic pathways of cells. Factors like variable sensitivity 
to different levels of ROS and also the sub-cellular localization of these antioxidants define 
the roles of these antioxidants in the diverse metabolic processes. 
Figure 3
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1.7.3.1 Localization of antioxidants
Although, ROS can be produced locally, they can easily diffuse throughout the cytosol and 
through the membranes of cell organelles [136, 144, 148]. To protect the cells from oxidative 
damage, it is important to have antioxidant systems at the site of ROS production. Antioxi-
dants have a distinct sub-cellular localization. Some antioxidants are localized in the cyto-
plasm, like peroxiredoxin isoforms- Prdx1, Prdx2 and Prdx6 [161]. Other peroxiredoxins are 
localised either in the mitochondria (Prdx3) or within the ER (Prdx4) or within peroxisomes 
(Prdx5), which are the major sites of ROS production in cells [161]. Other antioxidants like 
glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) are also pres-
ent at the major sites of ROS production in the mitochondria or peroxisomes. 
1.7.3.2 Sensitivity of antioxidants to oxidative inactivation
Cells express a variety of antioxidant enzymes like catalase, superoxide dismutase, thioredoxin 
(Trx), glutathione peroxidases and peroxiredoxins. Each of these antioxidants vary in their 
sensitivity to quantities of ROS. The enzymatic activities of GPx and catalase are maximal 
under 5mM and 30mM H2O2 concentrations respectively [162-163]. At such high concentra-
tions of hydrogen peroxide, peroxiredoxins are irreversibly inactivated. The amount of ROS 
produced upon receptor activation ranges between 10μM and 1mM [153]. The concentration 
of peroxide required to achieve half maximal activity for peroxiredoxins has been reported 
to be less than 20μM [164]. Most likely because of the high sensitivity of peroxiredoxins 
to small concentrations of ROS produced, they are more critical for signaling in cells. The 
other antioxidants which are less sensitive to small changes in ROS might be responsible for 
protection of cells under conditions of oxidative stress. 
1.8  PEROxIREdOxINS aNd ThEIR ROLE IN SIGNaLING
The peroxiredoxin family of antioxidants consists of 6 members (Prdx1-6). The peroxiredox-
ins are classified into typical 2 Cys-peroxiredoxins (Prdx 1 to 4), atypical 2-Cys peroxiredoxin 
(Prdx5) and 1-Cys peroxiredoxin (Prdx6), based on the number and the position of cysteine 
residues involved in their redox activities [161]. The N-terminal cysteine takes part in the 
peroxidase activity. In presence of peroxide the thiol group of Prdx undergoes oxidation 
to form a sulfenic acid (Figure 4). This oxidized state is easily reversed back to the active 
state by another antioxidant, thioredoxin (Trx). Trx itself also plays an important role in 
signaling (section 1.9). The sulfenic acid derivative can undergo further oxidation to form 
a sulfinic acid derivative. The sulfinic acid derivative can also be recycled back to the active 
thiol group by sulfiredoxin (Srx). Further oxidation of the sulfinic acid under conditions of 
oxidative stress leads to the formation of sulphonic acid derivative. This super oxidized state 
of peroxiredoxins is irreversible. 
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figure 4: Inactivation of peroxiredoxins by ROS
Upon oxidation, the cysteine in the catalytic site of antioxidants is converted into sulfenic acid thereby leading to 
inactivation of peroxiredoxins. The sulfenic acid derivative can be easily reactivated by thioredoxin. Sulfenic acid 
can be further oxidized to form sulfinic acid which can be further oxidized under conditions of oxidative stress to 
sulphonic acid. The sulphonic acid form is an irreversibly oxidized form. However the sulfinic acid derivative can be 
reactivated by reduction by sulfiredoxin (Srx). 
In response to growth factors, Prdx1 and Prdx2 are transiently inactivated by different 
mechanisms. Prdx1 undergoes Y194 phosphorylation-mediated-inactivation upon stimula-
tion with EGF/ PDGF. Only the fraction of Prdx1 located in direct proximity of the plasma 
membrane underwent tyrosine phosphorylation-mediated-inactivation upon EGF/ PDGF 
treatment as compared to cytosolic Prdx1 [165]. Prdx2 is inactivated by hyperoxidation of 
the catalytic cysteine upon stimulation with PDGF or EGF [165]. This allows transient signal-
ing in cells in response to EGF and PDGF. 
As mentioned in section 1.7.3.1, different peroxiredoxins are distributed over different 
cellular compartments like cytosol, mitochondria, peroxisomes, endoplasmic reticulum 
[161]. The localization of Prdx4 is still subject to controversy, with some studies suggesting 
that Prdx4 is both a cytoplasmic and a secreted protein, whereas others suggest that Prdx4 is 
predominantly retained in the endoplasmic reticulum (ER) [166-168]. 
Peroxiredoxins are involved in recycling phosphatases implicated in signal transduc-
tion from an oxidized, inactive state back to their reduced, active, form as described in the 
previous sections of this chapter [131]. Peroxiredoxins also down modulate receptor medi-
Figure 4
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ated signaling. Direct evidence for the role of Prdx proteins in PDGFR-β signaling comes 
from studies performed in Prdx2-/- MEFS by Choi and others [151]. Prdx2 was shown to 
be recruited to the PDGFR-β where it indirectly stimulated dephosphorylation of the tyro-
sines of the PDGFR-β by means of activation of a phosphatase. In case of the EGF receptor, 
over-expression of Prdx2 leads to a decrease in PKB activation upon stimulation with EGF, 
suggestive of a role for Prdx2 in activation of the PTEN phosphatase [169]. It has been 
shown that over-expression of Prdx2 in cells leads to a block in the activation of NF-ĸB 
upon stimulation with TNFα [170]. Furthermore, the production of H2O2 upon stimulation 
with TNFα was also blocked in cells over-expressing Prdx2 [170]. In A431 cells that express 
EGF receptors abundantly, the over expression of Prdx4 decreased ROS production upon 
stimulation with EGF, as compared to controls [171]. Besides, Prdx4 not only interacted with 
thromboxane A2 receptor (TPβ) but also regulated the membrane levels of expression of TPβ 
under conditions of oxidative stress [166]. 
Increased amounts of ROS are produced in cells expressing the truncated 
∆715-CSfR as compared to those expressing the wild type G-CSfR. This sug-
gests that a mechanism involved in negative regulation of ROS is linked to the 
C-terminus of G-CSfR, a region that is lacking in the ∆715-G-CSfR. 
as antioxidants are responsible for down modulation of ROS levels, we in-
vestigated whether any antioxidants interact with the C-terminus of G-CSfR 
and if so, whether they regulate redox signaling pathways coupled to G-CSfR 
activation.
we studied the interaction between G-CSfR and peroxiredoxins and the effect 
peroxiredoxins have on G-CSfR mediated signaling and proliferation, which 
is reported in Chapter 2. 
Diseases that involve abnormal inflammatory and metabolic processes such as heart 
dysfunction, cancer, diabetes mellitus and neural disorders usually involve abnormal ROS 
generation or their regulation. PRDX4 transcript as well as protein levels decrease upon 
treatment of cancer cell lines with TNF-apoptosis inducing ligand (TRAIL) [172]. In MEFs, 
Ndy1, induces expression of antioxidant proteins including Prdx4 [173]. Ndy1, a histone H3 
demethylase, is also known to protect cells from oxidative damage. Methylation of lysine 36 
of histone H3 (K36me2) of promoter leads to repression of transcription [174]. Ndy1 binds 
to specific sites in the Prdx4 promoter and demethylates H3K36-me2 associated with the 
promoter of Prdx4 thereby inducing its expression. A unique case of AML showing involve-
ment of PPRDX4 locus in a fusion with AML1 (RUNX1) carrying the t(X;21)(p22;q22) has 
been reported [175]. 
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a class of leukemia, namely the acute promyelocytic leukemia (aPL) bearing 
the t(15;17) translocation is associated with hyper responsiveness to G-CSf 
treatment.
we examined whether the expression of peroxiredoxins involved in down 
regulation of G-CSfR signaling is suppressed in aPL thereby leading to hyper 
responsiveness to G-CSf treatment. 
Chapter 3 of this thesis addresses these studies.
1.9 ThIOREdOxIN aNd ThIOREdOxIN INTERaCTING PROTEIN
As mentioned in section 1.8, the antioxidant thioredoxin (Trx) is responsible for reducing 
the sulfenic acid derivative of inactive peroxiredoxins to the thiol groups thereby resulting 
in their activation. Besides peroxiredoxins, thioredoxins catalyse the reduction of disulphide 
bonds in many proteins. In the process of reducing the disulphide bonds of substrates, Trx 
itself gets inactivated because of oxidation of cysteines in its catalytic site. Inactivated thiore-
doxin is reactivated by the thioredoxin reductase (TrxR) and NADPH [176-177]. 
Besides its oxido-reductase function, Trx carries out other functions via its binding 
partners. In its reduced state, Trx binds to transcription factors like AP-1 and NF-ĸB and 
modulates their DNA binding activity [178-180]. The best studied interaction of Trx is that 
with apoptosis signaling-regulating kinase 1 (Ask1) (Figure 5) [181]. Only reduced Trx is able 
to bind Ask1 and inhibit the activity of Ask1. Txnip (Thioredoxin-interacting protein) also 
known as Vdup1 (vitamin D3 upregulated protein 1) or Tbp2 (thioredoxin binding protein 
2) is another protein that binds Trx. Txnip was originally identified in HL-60 cells as the gene 
upregulated upon treatment of these cells with 1α,25-dihydroxyvitamin D3 [182]. Txnip was 
found to negatively regulate Trx function as well as its expression [183]. Txnip interaction 
with Trx requires the same domian of Trx as required for interaction of Trx with Ask1 [184-
185]. Thus Txnip and Ask1 compete with each other for interaction with Trx. The inhibitory 
effect of Txnip on Trx causes increased ROS levels thereby leading to oxidative stress in cells 
[184]. 
1.9.1 Role of Txnip in disease and tumorigenesis
The gene encoding Txnip was identified as a common virus integration site (VIS) in murine 
myeloid leukemias induced by Graffi 1.4 and Cas-Br murine leukemia viruses [186]. Txnip-/- 
mice show severely reduced numbers of natural killer (NK) cells as compared to wild type 
controls [187]. Also the activity of NK cells was severely reduced in Txnip knockout mice. 
Studies done in the Txnip knockout mice also suggest that Txnip plays a role in Krebs cycle 
mediated fatty acid utilization [188].
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figure 5: Role of Txnip
The major role of Txnip is to inhibit the activity of antioxidant protein Trx by physically interacting with Trx. Besides, 
inhibition of Trx function, Txnip also plays a role in other processes, like inducing cell cycle arrest, Krebs cycle and 
NK development. Txnip not only inhibits the activity of Trx but indirectly also that of Prdx.  
Txnip has been suggested to act as a tumor suppressor [189-190]. For instance, increased 
expression of Txnip leads to decreased proliferation of stomach cancer cell lines and a pro-
myelocytic leukemia cell line [190] and also prevents metastasis in transplantation models 
[189]. Enforced expression of Txnip resulted in a cell cycle arrest [190]. Txnip was shown to 
induce a cell cycle arrest by affecting several cell cycle regulators like p16Ink4a [191] and p27Kip1 
[192]. The stability of p27kip1, the cell cycle inhibitor, was found to be regulated by Txnip-Jab1 
[192]. c-Jun activation domain-binding protein-1 (Jab1) controls the stability and intracel-
lular distribution of p27Kip1 [193]. Binding of Txnip to Jab1 prevents translocation of p27kip1 
to the cytoplasm. In HTLV infected T cells with reduced p16Ink4a expression, the loss of Txnip 
expression was required for progression towards adult T cell leukemia (ATL) [191]. Txnip, 
via interaction with thioredoxin, not only inhibits the activity of thioredoxin but also that 
of peroxiredoxins. Blocking activities of two different antioxidant enzymes might result in 
increased ROS production thereby resulting in oxidative stress and DNA damage in cells.
Figure 5
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Injection of Graffi 1.4 murine leukemia virus causes aML in mice. Integration 
of the virus in the genome disrupts normal gene expression in cells. Txnip was 
identified as a common integration site in the insertional mutagenesis screens 
performed. 
we investigated whether viral integrations in Txnip, deregulate Txnip expres-
sion and whether these integrations play an important role in leukemogenesis. 
In chapter 4 of this thesis we address these questions.
These studies are reported in Chapter 4.
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Reactive oxygen species (ROS) regulate growth factor receptor signaling at least in part by 
inhibiting oxidation sensitive phosphatases. An emerging concept is that ROS act locally 
to affect signal transduction in different subcellular compartments and that ROS levels are 
regulated by antioxidant proteins at the same local level. Here, we show that the ER-resident 
antioxidant peroxiredoxin 4 (Prdx4) interacts with the cytoplasmic domain of the G-CSF 
receptor (G-CSFR). This interaction occurs when the activated G-CSFR resides in early en-
dosomes. Prdx4 inhibits G-CSF-induced signaling and proliferation in myeloid progenitors, 
depending on its redox-active cysteine core. The protein tyrosine phosphatase 1b (Ptp1b) 
appears to be a major down stream effector controlling these responses. Conversely, Ptp1b 
may keep Prdx4 active by reducing its phosphorylation. These findings unveil a new signal 
transduction regulatory circuitry involving redox-controlled processes in the ER and acti-
vated cytokine receptors in endosomes. 




Reactive oxygen species (ROS) are generated by nicotinamide adenine dinucleotide phos-
phate oxidase (Nox) complexes. In phagocytes the Nox system mainly serves to produce 
high levels of H2O2 for the so-called oxidative burst, a major weapon in host defence against 
bacteria. In non-phagocytic cells, H2O2  has long been considered as an unwanted by-product 
of cell metabolism, potentially hazardous because of the damaging effects on proteins, lipids, 
carbohydrates and nucleic acids [1-2]. There is increasing evidence that moderate levels 
of ROS are pivotal for many cellular processes, including the control of cell proliferation, 
survival and differentiation. For example, H2O2 inactivates enzymes, in particular protein ty-
rosine and lipid phosphatases, involved in growth factor signaling [1]. As a consequence, the 
signal magnitude and duration from cell surface receptors, such as platelet-derived growth 
factor receptor (PDGFR), interleukin 3 receptor (IL-3R), granulocyte-macrophage colony-
stimulating factor receptor (GM-CSFR) and G-CSFR is increased [3-5]. An important new 
insight that emerges is that ROS are produced in specific subcellular compartments and act 
locally to modulate signaling responses in different organelles [1,6]. 
In view of the local actions of ROS, an attractive hypothesis is that their levels are being 
controlled by nearby antioxidants, but evidence supporting this concept remains limited. 
Proteins of the peroxiredoxin (Prdx) family are major candidates for such local antioxidant 
activities [7]. Prdx proteins contain a core of usually 2 cysteines responsible for their redox 
activity [7]. Prdx1 and Prdx2 were found to associate with PDGFR and to modulate signal-
ing by controlling H2O2 levels at the plasma membrane [8-9]. Importantly, PDGFR-induced 
tyrosine phosphorylation of Prdx1 temporarily reduced its antioxidant activity, thereby al-
lowing a transient accumulation of H2O2 and inhibition of phosphatase activity in the vicinity 
of the plasma membrane [9]. Among the 6 mammalian Prdx proteins [7], Prdx1, 2, and 6 
are cytosolic, Prdx3 mitochondrial and Prdx5 peroxisomal. The exact localization of Prdx4 
has been somewhat ambiguous, but recent studies suggest that Prdx4 resides mainly in the 
endoplasmic reticulum (ER) [10-12]. 
Granulocyte colony-stimulating factor (G-CSF) is the major hematopoietic growth factor 
involved in the production of neutrophils [13-15]. G-CSF induces the proliferation, survival 
and neutrophilic differentiation of myeloid progenitor cells, cellular responses that require a 
balanced activation and subsequent attenuation of signaling pathways linked to the G-CSFR 
[15], a member of the cytokine receptor class I superfamily [16]. Signal attenuation of the G-
CSFR is severely compromised by mutations causing truncations in the cytoplasmic domain 
of the G-CSFR, as observed in severe congenital neutropenia (SCN) patients showing disease 
progression to acute myeloid leukemia (AML) [17-19]. A major mechanism implicated in the 
perturbed signaling functions of these truncated G-CSFR mutants is the loss of appropriate 
receptor endocytosis and lysosomal routing. These processes are controlled by a dileucine-
based internalization motif [20-21] and by receptor ubiquitination involving the suppressor 
of cytokine signaling protein SOCS3 [22-26]. 
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Here, we investigated whether Prdx proteins control signaling from G-CSFR and in which 
subcellular compartment this takes place. In contrast to PDGFR, G-CSFR does not bind 
Prdx1 and Prdx2, but exclusively interacts with Prdx4. This interaction takes place during 
retrograde routing, when the activated G-CSFR resides in early endosomes. Prdx4 attenu-
ates G-CSF-induced STAT activation and proliferation, and this depends on the integrity 
of its redox active cysteine core. The tyrosine phosphatase Ptp1b, known to reside in the ER 
[27-28], appears the major target for Prdx4-controlled modulation of G-CSF responses. In 
its turn, Ptp1b reduces Prdx4 phosphorylation, which by analogy to Prdx1 may keep Prdx4 
in an active state. These findings identify the ER as an important signaling organelle control-
ling G-CSF responses of myeloid progenitors and provide insight into the complex interplay 
between redox-controlled processes and receptor signaling at the boundary between ER and 
retrograde endocytotic vesicles. 
MaTERIaLS aNd METhOdS
PCR primers
Primers used for the preparation of constructs are listed in Table S1. All PCR products were 
checked for correct nucleotide sequences.
G-CSfR expression constructs
The G-CSFR WT and K5R expression constructs have been described previously [25]. To 
create G-CSFR-Prdx4 fusions, the G-CSFR part was amplified using primers Fw7 G-CSFR 
and Δ73Prdx4-Δ795GR Rv (Table S1). A glycine-glycine-serine (GGS) flexible linker was 
introduced between G-CSFR and Prdx4. For amplification of ∆73 Prdx4, primers Δ73Prdx4 
Δ795GR Fw and Rv Prdx4 EcoRV were used. These fragments were used as a template for the 
fusion PCR, performed with primers Fw7 G-CSFR and Rv Prdx4 EcoRV. The fusion product 
was cloned as an EcoRV-HpaI fragment into the pBABE-wt-G-CSFR vector. Multisite-
directed mutagenesis kit from Stratagene (Huissen, The Netherlands) was used to mutate 
both cysteines in the active site of Prdx4, using Δ795-G-CSFR- Δ73Prdx4 as a template. 
Cells, retroviral transduction and transfection
Mouse bone marrow progenitor cells were isolated as described [29] and transduced with 
pBABE virus generated in Phoenix E cells expressing the different G-CSFR constructs. 
Cells were pre-cultured for two days in CellGro medium supplemented with IL-3 (10 ng/
mL), Flt3-ligand (FL) (50 ng/mL), stem cell factor (SCF) (10 ng/mL) and thrombopoietin 
(Tpo) (10 ng/mL) [23]. 32D cells were transduced with the same retroviral constructs, as 
described [29]. For each construct, multiple independent clones were expanded for further 
analysis. Mouse embryonic fibroblasts were transduced with virus generated by transfection 
of Phoenix E cells with pBABE/ wt-G-CSFR. Cells expressing wt-GCSFR were selected us-
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ing puromycin (1.5µg/mL) selection. HekT cells were transiently transfected using calcium 
phosphate precipitation, and HeLa cells were transfected using lipofectamine (Invitrogen, 
Breda, The Netherlands).
Mammalian Protein-Protein Interaction Trap (MaPPIT) assay
Bait Constructs. G-CSFR fragments were cloned in-frame with the MAPPIT bait receptor, 
consisting of the extracellular domain of the EPO receptor and the cytoplasmic domain of 
leptin receptor lacking Stat3-binding sites, as described [29]. 
Prey Constructs. Prdx1, 2, 4 and 6 sequences were amplified from HL60 cells using forward 
primers with a 5`EcoRI site, followed by the respective Prdx sequence. The reverse primers 
were designed with an XhoI restriction site 3’of the STOP codon. The Prdx fragments were 
cloned into the pMG2 prey vector [30], thus generating the FLAG-tagged Prdx-gp130 fu-
sion constructs. Prey-bait interactions were quantified in Stat3 luciferase assays as described 
[29-30]. In brief, HekT cells (2 x 105) were transfected with bait and prey constructs along 
with a luciferase reporter (pXP2d2-rPAP-Luci). 48 hours after transfection, the chimeric bait 
receptors were activated with Epo (0.5 U/ml) for 24 hours or left unstimulated. Luciferase 
activity from Stat3 luciferase reporter was determined using the Steady Glo luciferase assay 
system (Promega, Leiden, The Netherlands).
antibodies and fluorescent reagents  
Prdx4 rabbit polyclonal (Ab15574), Prdx4 mouse monoclonal (Ab16943) and GRP94 rabbit 
polyclonal (Ab3674) antibodies were purchased from Abcam (Cambridge, UK). Goat poly-
clonal antibodies against EEA1 (sc6414) and β-actin (sc1616) were purchased from Santa 
Cruz Biotechnology Inc, (Santa Cruz, CA, USA). Mouse anti-human G-CSFR (CD114) was 
from Becton Dickinson (Franklin Lakes, NJ, USA); p-Stat3 (Tyr 705 and Ser 727), p-Akt 
and phospho-Jak2 (Y1007/1008) antibodies were from Cell Signaling Inc (Danvers, MA, 
USA) and anti phosphotyrosine 4G10 and 4G10-biotin antibodies from Millipore (Billerica, 
MA, USA). The latter were visualized on Western blots using Streptavidin-IRDye800CW 
(LI-COR, Lincoln, NE, USA).  Secondary donkey anti- rabbit Cy3 and donkey anti-mouse 
Cy5 antibodies used for confocal imaging were from Jackson Immunoresearch (Suffolk, UK). 
ERGIC-53 rabbit polyclonal antibody (E1031) was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). 
Immune precipitations, bio-G-CSf pull-downs and western blotting
HekT cells transfected with pBABE/G-CSFR were placed for 4 hrs in DMEM without FCS 
and then stimulated with G-CSF (100ng/mL). After stimulation, cells were lysed at 4oC in lysis 
buffer (50mM Tris-HCL pH 7.4, 50mM NaCl, 10% glycerol, 1% NP40, 0.5% Na-deoxycholate, 
20mM NaF) containing a cocktail of protease inhibitors. Lysates were incubated overnight at 
4°C with pre-washed Protein G Dynabeads (Invitrogen/ DYNAL) coated with Prdx4 mouse 
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monoclonal antibody purchased from Abcam. Immune complexes were visualized by west-
ern blotting. To study tyrosine phosphorylation of the G-CSFR, pull-down of G-CSFR using 
biotinylated G-CSF and streptavidin-coated beads was performed as described [26].
Confocal microscopy scanning microscopy (CLSM)
HeLa cells transiently transfected with pLNCX2/G-CSFR (WT) were used for CLSM. 
Forty-eight hours after transfection, HeLa cells were growth factor- and serum- deprived by 
incubation for 4 hrs in DMEM. G-CSFR antibody (2.5μg/mL) was added to the medium and 
incubated at room temperature for 20 min to allow binding of the antibody to the extracel-
lular domain of the G-CSFR. Excess antibody was washed off and cells were stimulated with 
G-CSF for different time periods. Immune-staining was performed as described previously 
[25]. Cells were imaged using the multi-track detection mode on a Zeiss LSM 519 confocal 
microscope equipped with Argon/HeNe lasers using a 63x Planochromat oil immersion 
objective.
Colony assays
Retrovirally transduced Csf3r-/- bone marrow cells. Forty-eight hours after retroviral infection, 
cells were harvested and placed in methocult (M3231, Stem Cell Technologies Inc., Van-
couver, Canada) containing puromycin (1.5 μg/mL) and either human recombinant G-CSF 
(100 ng/mL, Amgen, Breda, The Netherlands) or mouse GM-CSF (20 U/mL, Peprotech Inc., 
USA). All cultures were done in triplicate and colonies were counted on day 7 of culture.
Prdx4-/- and Ptp1b-/- bone marrow cells. Femurs, tibiae and sterna from Prdx4-/- [31], Ptp1b-/- 
and age and sex matched control mice [32] were shipped on ice from the Fujii and Neel labs. 
Bone marrow mononuclear cells were obtained as described [33] and cultured in colony 
assays with different concentrations of G-CSF or one standard concentration of GM-CSF (10 
ng/mL). 




Prdx4 interacts with the G-CSfR
In an earlier yeast two hybrid screen, we identified peroxiredoxins as putative G-CSFR-inter-
acting proteins. To assess whether these interactions occur in mammalian cells, we used the 
mammalian protein-protein interaction trap (MAPPIT) assay [30]. Bait and prey constructs 
are shown in Figure 1A. Prdx3 and Prdx5 were excluded from this analysis because of their 
mitochondrial and peroxisomal localizations, respectively. After a series of standard positive 
and negative controls to assure specificity of the system (Figure S1), we performed experi-
ments with the Prdx prey constructs and found that Prdx4, but not Prdx1, 2, or 6, interacted 
with the G-CSFR C-terminus (Figure 1B). Using additional bait constructs, we identified 
the distal region spanning amino acids 792-813 as the major PRDX4 binding site (Figure 
1C). This region does not show sequence homology with other cytokine receptors. To assess 
whether the integrity of the cysteine core of Prdx4 is required for its interaction with G-CSFR, 
we generated Prdx4 prey constructs in which both cysteines in the active site were changed 
into serines (Prdx4mut). Prdx4 and Prdx4mut prey constructs showed comparable binding 
to the G-CSFR baits, implying that the redox status of Prdx4 does not affect this interaction 
(Figure 1D). Prdx4 differs from the other family members in that its N-terminus has a 73 
amino acid extension, including a predicted signal peptide of 37 amino acids. Deletion of the 
N-terminal region abolished MAPPIT activity, suggesting that this region is predominantly 
responsible for Prdx4 binding to the G-CSFR (Figure 1E). Conversely, a prey construct con-
sisting of only the N-terminal 73 amino acids (N73a.a.-Prdx4) interacted with the G-CSFR 
bait, confirming the importance of the Prdx4 N-terminus for G-CSFR binding (Figure 1F). 
In immune precipitation experiments, G-CSFR co-precipitated with endogenous Prdx4 from 
lysates of HEK293 cells ectopically expressing WT G-CSFR, confirming the results from the 
MAPPIT assay. However, under these conditions basal Prdx4 binding to G-CSFR was seen, 
indicating that the physical interaction between G-CSFR and Prdx4 proteins per se does not 
depend on receptor activation (Figure S2). 
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figure 1. MaPPIT assay of Prdx/G-CSfR interactions
(a) Schematic representation of bait and prey MAPPIT constructs. (b) MAPPIT with G-CSFR-C65 (a.a. 749-813) 
bait and Prdx1, Prdx2, Prdx4 and Prdx6 prey constructs showing specific interaction with Prdx4. (C) Mapping 
of domains of the G-CSFR involved in Prdx4 binding. FL: full length G-CSFR cytoplasmic domain; 686-735 and 
736-774 represent isolated amino acid stretches within the G-CSFR cytoplasmic domain; C65∆ mutants represent 
C-terminal deletions of C-CSFR-C65 bait; EV: empty bait vector control. (d) MAPPIT showing that cysteines in the 
active sites of Prdx4 (Cys 124 and Cys 245) are not involved in interaction of Prdx4 with G-CSFR-C65. (E) Loss of 
Prdx4 binding to G-CSFR upon deletion of the specific extended N-terminus of Prdx4 (∆73Prdx4). (f) Binding of 
the N-terminal region of Prdx4 (N73 a.a Prdx4) to C65-G-CSFR. Full length Prdx4 and Prdx2-containing preys were 
included as positive and negative controls, respectively.
Co-localization of endocytosed G-CSfR with Prdx4 residing in the ER/ERGIC 
We subsequently used confocal microscopy to study where Prdx4 and G-CSFR interact in 
intact cells. Prdx4 did not co-localize with G-CSFR at the cell surface. Thirty minutes after 
G-CSF treatment, when G-CSFR resided in EEA1 positive early endosomes, co-localization 
with Prdx4 was maximal and declined after 1 hr, when the G-CSFR was present in late 
endosomes and lysosomes (Figure 2A and Figure S3). In contrast, co-localization of the 
lysosomal routing defective G-CSFR mutant K5R persisted at 60 min after G-CSF stimula-
tion, confirming that Prdx4 interacts with G-CSFR localized in early endosomes [25-26] 
(Figure S4a). Quantification of these data is shown in Figure S4b. As expected based on the 
MAPPIT experiments, no significant co-localization of Prdx2 and G-CSFR was detectable, 
neither at the plasma membrane nor in endocytotic vesicles (Figure S5). Because Prdx4 was 
detected mainly in the ER and ER-Golgi intermediate compartment (ERGIC), with only a 
minor fraction in the Golgi (Figure S6), these findings imply that the interaction between 
G-CSFR and Prdx4 takes place when the endocytosed G-CSFR complexes are in proximity 
of the ER/ERGIC. Supporting this, G-CSFR also co-stained with ER marker Grp94 and with 
ERGIC marker ERGIC-53 after ligand-induced internalization (Figure 2B). 
Prdx4 inhibition of G-CSf-induced proliferation of myeloid progenitor cells requires 
the integrity of its cysteine core 
To directly study the functional implications of Prdx4 binding on G-CSFR signaling and 
to determine the role of the redox-active cysteines herein, we fused the catalytic domain of 
Prdx4 and the mutant domain missing the critical cysteines directly to G-CSFR-∆795. G-CS-
FR-∆795 was chosen because it lacks a major C-terminal domain responsible for endogenous 
Prdx4 binding as identified by MAPPIT (Figure 3A). Although a drawback of this approach 
is that the interaction with Prdx4 is constitutive, rather than temporal and dependent on 
endocytotic routing, routing of the G-CSFR towards the ER/ERGIC was not affected by the 
Prdx4 fusion (Figure S7A). Hence, Prdx4 is still able to function in this setting at the ER-
early endosome interface. We first transduced 32D cells with these constructs and selected 
clones with comparable expression of WT G-CSFR, G-CSFR-∆795, G-CSFR-∆795-Prdx4 
and G-CSFR-∆795-Prdx4mut at the plasma membrane (Figure S7B), allowing comparisons 
of their signaling abilities at equal receptor densities. Relative to 32D/WT, 32D/∆795 clones 
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figure 2. G-CSfR and Prdx4 interaction and co-localization 
(a) HeLa cells ectopically expressing WT G-CSFR were growth factor-deprived for 4 hrs. Surface membrane 
G-CSFRs were labelled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx4 antibody, followed by secondary and anti-rabbit Cy3 and anti-
mouse Cy5 antibodies, and analyzed by CLSM.  (b) Co-localization of endocytosed G-CSFR with Grp94-stained ER 
and with ERGIC 30 min. after ligand stimulation. Experimental conditions were the same as under B. 
showed increased proliferation in response to G-CSF, whereas the proliferation rate of 
32D/∆795-Prdx4 clones was similar to 32D/WT clones (Figure 3B). It contrast, 32D/∆795-
Prdx4mut clones showed the same elevated proliferation rate as and 32D/∆795 clones, indi-
cating that the redox-active thiol group of Prdx4 confers growth inhibition (Figure 3B). No 
differences in proliferation rates of these clones were seen in interleukin 3-containing cultures 
(not shown). To extend these observations to primary myeloid progenitors, we transduced 
bone marrow cells from Csf3r-/- mice with the above-mentioned G-CSFR constructs using the 
BABE retroviral vector (conferring puromycin resistance), and cultured these cells in colony 
cultures supplemented with G-CSF or GM-CSF and puromycin. GM-CSF-induced colonies 
did not differ significantly between the constructs, indicative of comparable transduction 
efficiencies, (Figure 3C). In line with the findings in 32D cells, G-CSFR-∆795-expressing BM 
cells produced higher numbers and greater-sized colonies, whereas G-CSFR-∆795-Prdx4-
expressing BM cells generated significantly fewer and smaller colonies in response to G-CSF 
compared to wt G-CSFR-expressing BM cells (Figure 3C). As in 32D cells, this effect of Prdx4 
depended on the integrity of the redox active cysteines.
Prdx4 attenuates G-CSf-induced STaT3 activation 
To identify the signaling pathways that are modulated by Prdx4, lysates of 32D clones express-
ing the different G-CSFR forms were subjected to western blotting with phospho-specific 
antibodies to detect activation of Stat3, Stat5 and Akt. In experiments in which cells were 
first growth factor and serum deprived and then stimulated with G-CSF for up to 120 min, 
fusion of active Prdx4, but not the inactive mutant, inhibited Stat3 phosphorylation (Figure 
4A). In long-term cultures, in which cells were switched from IL3- to G-CSF-containing 
culture medium and lysates made every 2 days, p-Stat3 levels were again markedly reduced 
in 32D/∆795-Prdx4 clones compared to 32D/∆795-Prdx4mut (Figure 4B). In contrast, no 
significant differences were seen in Stat5 and Akt phosphorylation (not shown). A possible 
explanation for this difference is that G-CSF-induced Stat3 activation requires recruitment 
of Stat3 to phosphotyrosines in the G-CSFR membrane distal cytoplasmic region, whereas 
Stat5 and Akt activation occurs through the membrane proximal G-CSFR region without 
the involvement of receptor tyrosines [34-36]. Moreover, Akt phosphorylation is already 
downregulated early in G-CSFR endocytosis, i.e., before endosome-ER contacts take place 
and Prdx4 modulates G-CSFR signaling[25].
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figure 3. Prdx4 attenuates G-CSf-induced proliferation in myeloid progenitors depending on its active 
cysteine core 
(a) Schematic representation of G-CSFR-Prdx4 fusion constructs. For details see Material and Methods. 
(b) Proliferation of 32D cells expressing constructs shown in panel A. Cells were cultured in 10ng/ml G-CSF. 
Data represent the means ± standard deviation of 5 independent clones for each transfectant. (C) Colony assay 
of csf3r-/- bone marrow cells transduced with constructs shown in panel A. Transduced bone marrow cells 
(50,000) were plated in triplicate in medium containing either G-CSF or GM-CSF and puromycin as a selection 
marker. Colonies were counted on day 7 of culture (upper panel). Data are expressed as the mean of triplicate 
cultures ± s.d. Lower panel: representative photomicrographs showing differences in colony size. 
c.
Figure 3
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figure 4. Prdx4 and Ptp1b attenuate 
G-CSfR signaling
(a) 32D cells expressing G-CSFR-
Prdx4 fusion and control constructs 
(Figure 3A) were first growth factor-
deprived for 4 hrs and then stimulated 
with 100ng/ml for the indicated times. 
(b) Western blot analysis of p- Stat3 
levels in the same 32D cell transfec-
tants at 0, 2 and 4 days of culture with 
100 ng/mL of G-CSF. b-actin staining 
was performed for loading control. (C) 
Western blot analysis of p- Stat3 in WT 
and Prdx4-/- MEFs stably expressing 
G-CSFR after serum deprivation and 
G-CSF stimulation for indicated times. 
WT and Prdx4-/- MEFs expressed 
comparable G-CSFR expression levels 
as determined by flow cytometry. (d) 
Colony assay of Prdx4-/- and WT litter-
mate control bone marrow cells. Cells 
(50,000) were plated in triplicate in 
me thocult containing either G-CSF or 
GM-CSF and puromycin as a selection 
marker. Colonies were counted on day 
7 of culture. Data are expressed as the 
mean of triplicate cultures ± s.d.  
Figure 4
KP.indd   55 28-2-2011   11:53:42
56
Chapter 2
Increased G-CSf-induced Stat3 activation and myeloid colony formation in Prdx4-/- cells 
Having shown that enforced interaction of Prdx4 with G-CSFR attenuates G-CSF signaling 
in myeloid progenitors, we investigated how depletion of Prdx4 affects G-CSF signaling. To 
this end, we transduced Prdx4-/- and wild type mouse embryonic fibroblasts (MEFs) with 
the G-CSFR and assessed phosphorylation of Stat3, Stat5 and Akt. Phospho-Stat3 levels 
were significantly increased in Prdx4-/- cells relative to wild type controls (Figure 4C). Again, 
phospho-Akt levels did not significantly differ between Prdx4 deficient versus proficient 
cells, while phospho-Stat5 was below detection level in these cells (data not shown). To ad-
dress whether Prdx4 deficiency affects G-CSF signaling in primary hematopoietic cells, we 
performed colony cultures with increasing concentrations of G-CSF. Prdx4-/- bone marrow 
cells yielded significantly higher numbers of colonies relative to wild type littermate control 
cells at different concentrations of G-CSF (Figure 4D). In contrast, GM-CSF-induced colony 
growth did not differ between Prdx4-deficient and wild type bone marrow cells, showing that 
G-CSF, but not GM-CSF, signaling is controlled by Prdx4. 
Ptp1b inhibits G-CSf-induced signaling and proliferation of myeloid progenitors
Ptp1b resides at the ER [28, 37], is highly sensitive to oxidation [38] and is therefore a likely 
down stream effector of Prdx4-modulated signaling. We confirmed the co-localization of 
Ptp1b and Prdx4 in the ER and ERGIC compartments in primary bone marrow cells (Figure 
S8). Biotinylated G-CSF pull-down showed that Ptp1b interacts with G-CSFR (Figure 5A). 
Western blot analysis in Ptp1b-/- and Ptp1b reconstituted MEFs transduced with G-CSFR 
showed significantly elevated G-CSF-induced Jak2 and Stat3 phosphorylation in the Ptp1b-
/-cells (Figure 5B). Similar to Prdx4-deficient cells, phospho-Akt levels were unaffected by 
Ptp1b depletion (Figure 5B). Colony cultures with Ptp1b-/- bone marrow cells also yielded 
results comparable to those obtained with Prdx4-deficient cells, showing elevated numbers 
and significantly greater-sized colonies in response to G-CSF, with GM-CSF-induced colony 
formation unchanged relative to Ptp1b+/+ controls (Figure 5C). 
Ptp1b reduces phosphorylation of both G-CSfR and Prdx4
We then asked whether Ptp1b controls ligand-induced G-CSFR phosphorylation. For this, 
we performed off-rate experiments, in which cells were stimulated for 10 min with G-CSF, 
where after the cells were washed and further cultured without growth factor. Tyrosine 
phosphorylation of G-CSFR was elevated and prolonged in Ptp1b-/- MEFs compared to the 
reconstituted control cells (Figure 6A). Supporting the notion that Ptp1b reduces G-CSFR 
phosphorylation in early endosomes, this difference was even more pronounced in cells 
expressing G-CSFR mutant K5R (Figure 6B). Finally, because phosphorylation of Prdx1 
has been reported to decrease its activity [9], we investigated whether Ptp1b controls the 
phosphorylation status of Prdx4. Prdx4 was clearly hyperphosphorylated in Ptp1b deficient 
MEFs compared to reconstituted cells (Figure 6C). This was also evident in the absence of 
G-CSF stimulation (Figure 6C), indicating that receptor signaling is not required for Ptp1b-
controlled phosphorylation of Prdx4. 
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figure 5. Ptp1b interacts with G-CSfR and attenuates signaling
(a) Ptp1b immunoprecipitations from Hek cells transfected with lysine-less pBABE-K5R-G-CSFR and pJ3H-Ptp1b-
HA constructs. Cells were growth factor-deprived for 4 hrs, followed by stimulation with biotinylated G-CSF for 
the indicated times. Precipitates were collected on streptavidin-coated beads. Blots were stained for G-CSFR and 
Ptp1b. TCL: total cell lysate. (b) Western blot analysis of p-Stat3, p-Jak2 and p-Akt in Ptp1b-/- and reconstituted 
MEFs stably expressing G-CSFR; stimulation conditions as in Figure 4C. b-actin staining served as loading control 
in all experiments. Ptp1b-/- and reconstituted MEFs expressed comparable G-CSFR expression levels as determined 
by flow cytometry.  (C) Colony assays of Ptp1b-/- and WT littermate control bone marrow cells. Culture conditions 
were similar to those described in panel A. Photomicrographs in lower panel show differences in colony size from 











figure 6. Increased tyrosine phosphorylation 
of G-CSfR and Prdx4 in Ptp1b deficient cells 
(a) Phosphotyrosine analysis of G-CSFR after 
BioG-CSF pull down in Ptp1b-/- or Ptp1b 
reconstituted MEFs expressing wt-G-CSFR. 
Ten min after addition of Bio-G-CSF, cells were 
washed and further cultured without growth 
factor. Histograms show quantifications of 
p-Tyr levels relative to total G-CSFR protein in 
BioG-CSF pull downs at the indicated times. 
Data shown are representative of 3 independent 
experiments. (b) Similar to (A) with lysine-less 
G-CSFR mutant K5R that accumulates in early 
endosomes. (C) Phosphotyrosine analysis of 
Prdx4 immunoprecipitates. Histograms show 
quantifications of p-Tyr levels relative immuno-
precipitated Prdx4. Data are representative of 2 
independent experiments. TCL: total cell lysate.




The key finding reported here is that the antioxidant protein Prdx4, localized in the ER, 
attenuates G-CSFR signaling from early endosomes. In addition, we provided evidence to 
suggest that this is achieved by preventing the loss of activity of the ER-resident tyrosine 
phosphatase Ptp1b. Recent studies have shown that different Nox complexes allocate to spe-
cific subcellular compartments [39-43] and act in spatially restricted microdomains, which is 
thought to be essential for specificity of ROS-mediated signaling [6]. For instance, the local 
action of Nox2 in a signaling module was demonstrated for interleukin-1 (IL-1) signaling: 
after activation of the IL-1 receptor, Nox2 controlled the binding of TRAF6 to the IL1R/
MyD88 complex in early endosomes [44]. Nox4, on the other hand has been shown to drive 
ROS signaling from the ER [43, 45]. A recent study on interleukin-4 (IL-4) receptor showed 
that ROS promotes IL-4 signaling by inhibition of Ptp1b [46]. Furthermore, Nox4 was shown 
to be responsible for ROS production in the ER and to be critical for the regulation Ptp1b, 
further illustrating specificity of intracellular ROS-controlled signaling depending on the 
localization of Nox isoforms within particular subcellular compartments [45]. Based on our 
findings and these recent reports, we propose a model in which Prdx4 negatively controls G-
CSF signaling by neutralizing ROS produced by Nox4 in the ER, thereby keeping Ptp1b in an 
active state (Figure 7). Conversely, Ptp1b inhibits tyrosine phosphorylation of Prdx4, which 
by analogy to Prdx1, may increase its activity [9]. Whether G-CSFR and Prdx4 are direct 
substrates of Ptp1b or whether Ptp1b acts mainly through dephosphorylation and inhibition 
of Jaks (Figure 5B and shown previously for interferon and leptin signaling [47-48]) is pres-
ently unknown. The latter appears the most likely, given that neither the G-CSFR cytoplasmic 
domain nor Prdx4 contains the Ptp1b recognition motif E/D-pY-pY-R/K present in Jak2 and 
Tyk2 [47, 49] Another still open question is whether Prdx4, in addition to its antioxidant 
function, acts as a tethering molecule, thereby stabilizing the interaction between G-CSFR 
and Ptp1b at the ER-early endosome interface.  
Our observation that Prdx4 co-localizes with the ER/ERGIC corroborates with an earlier 
report [12]. Based on structure prediction and resistance to proteinase K digestion, this study 
also suggested that Prdx4 resides inside the ER lumen [12]. Although this would be in apparent 
conflict with an interaction of Prdx4 with the G-CSFR cytoplasmic domain, proteins residing 
in the ER may retrotranslocate from the lumen and enter the cytoplasm. For instance this was 
demonstrated for the protein chaperone calreticulin [37, 50]. A similar process could explain 
how Prdx4 exits the ER lumen and binds to the cytosolic tail of G-CSFR. Possibly, an interac-
tion with the ER lipid bilayer or with binding proteins located herein would keep Prdx4 in 
proximity of the ER. Notably, in immunoprecipitations, G-CSFR also co-precipitated with 
Prdx4 in the absence of growth factor (Figure S2). This interaction might either occur after 
constitutive retrograde routing of G-CSFR, between Prdx4 and G-CSFR residing in forward-
routing vesicles or both, but whether this has any functional significance is presently unclear. 
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In conclusion, our study suggests that the antioxidant protein Prdx4 negatively controls 
G-CSF signaling in the early endosome compartment by reducing ROS levels in proximity of 
the ER, thereby keeping Ptp1b active. As a consequence, the tyrosine-based Stat3 docking sites 
in the G-CSFR are dephosphorylated, resulting in attenuation of Stat3 activation. Intrigu-
ingly, the G-CSFR truncation mutants found in SCN/AML respond differentially to SOCS3 
in terms of Stat3 versus Stat5 inhibition: whereas SOCS3-mediated inhibition of Stat5 activa-
tion is abolished as a result of the G-CSFR truncation, inhibition of Stat3 remained largely 
intact [51]. This discrepancy relates to the fact that SOCS3-induced Stat5 inhibition entirely 
depends on SOCS box-mediated ubiquitination of G-CSFR, whereas SOCS3-induced Stat3 
inhibition is less dependent on this process [25-26, 51]. Together with these previous results 
our current data suggest that, whereas attenuation of Stat5 mainly depends on lysosomal deg-
radation of the activated G-CSFR, Stat3 inhibition is mediated mainly by dephosphorylation 
of Stat3-binding tyrosine motifs controlled by the kinase inhibitory region of SOCS3 and by 
Ptp1b, when the G-CSFR resides in the early endosome. These findings support the idea that 
signal diversification from certain growth factor receptors is to a major extent determined 
by routing dynamics, a concept that becomes increasingly attractive to explain how growth 
factor receptors exerts specific functions, while activating largely overlapping signaling path-
ways. The dynamic interplay between ER-localized enzyme systems and activated receptors 
in endocytotic vesicles turns out to be a key event in this process. 
Deregulation of redox-controlled signaling pathways is increasingly implicated in a 
variety of diseases, including leukemia. For instance, the gene encoding Thioredoxin inhibi-
tory protein (Txnip), a common target for retroviral integration in murine leukemia virus-
induced mouse leukemia, appeared to be significantly upregulated in a subgroup of human 
AML patients [52]. A case of AML with a t(X;21)(p22;q22) has been reported in which the 
PRDX4 gene located on Xp22 was fused to RUNX1 at 21q22, resulting in a RUNX1-PRDX4 
fusion transcript [53]. We screened 65 MDS patients and 113 AML patients for possible 
mutations, but no mutations in the PRDX4 coding region were detected, suggesting that 
genomic aberrations affecting PRDX4 are rare in MDS/AML [54]. Intriguingly, this study 
also showed that PRDX4 expression is significantly down regulated in acute promyelocytic 
leukemia (APL) cells, involving H3K27 tri-methylation as a mechanism of histone-mediated 
gene silencing [54]. Although the role of PRDX4 down regulation in primary APL stem and 
progenitor cells remains to be established, predictably the loss of PRDX4 may lead to reduced 
ER-linked PTP1B activity, providing an explanation for the increased responsiveness of APL 
clonogenic precursors to G-CSF [55].
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figure 7. Model of Prdx4-controlled G-CSf signaling 
Activation of G-CSFR leads to internalization and entry in early endosomes. G-CSFR dephosphorylation is then 
mediated by Ptp1b, which requires endosomal trafficking of the G-CSFR towards the ER, where Ptp1b resides. Ptp1b 
activity is inhibited by ROS, which is locally produced in the ER by Nox4 [45]. ER-resident Prdx4 reduces ROS, 
thereby elevating Ptp1b activity. After or during dephosphorylation in early endosomes, G-CSFR ubiquitination 
takes place [26], which triggers routing to late endosomes and lysosomes, where G-CSFR are degraded. P: phosphate; 
U: ubiquitin.
Figure 7
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figure S1: MAPPIT with control bait and prey constructs to demonstrate specific interactions. Bait-prey combina-
tions p53-SVT and p53-CIS are general positive and negative MAPPIT controls, respectively. Interactions of G-CSFR 
C65 with Grb2, and C-Y (lacking Grb2-binding Tyr764 of the G-CSFR) with Grb2 are shown to support binding 
specificity in the context of G-CSFR. 
figure S2: Prdx4 immunoprecipitations from Hek cells transfected with pBABE-G-CSFR or pBABE-ev constructs. 
Cells were growth factor-deprived for 4 hrs, followed by stimulation with G-CSF for the indicated time points. Blots 
were stained for G-CSFR and Prdx4.
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figure S3: HeLa cells ectopically expressing wt-G-CSFR were growth factor deprived for 4 hrs. Surface membrane 
G-CSFRs were labeled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx4 and eea1 antibodies followed by secondary anti-goat 488, anti-
rabbit Cy3 and anti-mouse Cy5 antibodies antibodies and analyzed by CLSM.
S3
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figure S4a: HeLa cells ectopically expressing K5R-G-CSFR were growth factor deprived for 4 hrs. Surface membrane 
G-CSFRs were labeled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx4 antibody followed by secondary and anti-rabbit Cy3 and anti-
mouse Cy5 antibodies antibodies and analyzed by CLSM.
S4A
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figure S4b: Quantification of co-localizing wt-G-CSFR (grey bars) or K5R-G-CSFR vesicles (black bars) with endog-
enous Prdx4 upon stimulation with G-CSF.
S4B
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figure S5: HeLa cells ectopically expressing wt-G-CSFR were growth factor deprived for 4 hrs. Surface membrane 
G-CSFRs were labeled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx2 antibody followed by secondary and anti-rabbit Cy3 and anti-
mouse Cy5 antibodies antibodies and analyzed by CLSM.
S5
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figure S6: CLSM showing the co-localization of Prdx4 with markers for various sub-cellular compartments in HekT 
cells. The ER-Golgi-Intermediate Compartment was stained using an antibody against ERGIC, the ER with anti-









figure S7: (A) CLSM showing routing of G-CSFR-Prdx4 fusion protein towards ER and ERGIC comparable to 
WT G-CSFR
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figure S7: (B) Flow cytometric analysis of cell surface expression of G-CSFR constructs in 32D cells 








Name of the primer Sequence (5`-3`)
PRDX1 MAPPIT Fwd CGGAATTCATGTCTTCAGGAAATGCT
PRDX1 MAPPIT Rv GACTCCGAGTCACTTCTGCTTGGAGAA
PRDX2 MAPPIT Fwd CGGAATTCATGGCCTCCGGTAACGCG
PRDX2 MAPPIT Rv GACTCGAGCTAATTGTGTTTGGAGAA
PRDX4 MAPPIT Fwd CGGAATTCATGGAGGCGCTGCCGCTG
PRDX4 MAPPIT Rv GACTCGAGTCAATTCAGTTTATCGAAATAC
PRDX6 MAPPIT Fwd CGGAATTCATGCCCGGAGGTCTGCTT
PRDX6 MAPPIT Rv GACTCGAGTTAAGGCTGGGGTGTGAGCG
Fw7 G-CSFR GTCCTCACCCTGATGACC
∆73Prdx4 ∆795GR Rv TTAGGTGCAGTGATGATCCTCCGTTGAGCAGTGGCCCAAAGA
∆73Prdx4 ∆795GR Fwd ACTGCTCAACGGAGGATCACTGCACCTAAGCAAAGCGAA
Rv Prdx4 EcoRV CCGATATCTCAATTCAGTTTATCGAA
PRDX4mut R1 AATTTCAGTTGGAGACACAAATGTGAA
PRDX4mut R2 CCAGCCAGCAGGGGAGACTTCTCC
KP.indd   72 28-2-2011   11:54:01
KP.indd   73 28-2-2011   11:54:01
CHAPTER3
KP.indd   74 28-2-2011   11:54:01
3 The antioxidant protein peroxiredoxin 4  is epigenetically down regulated in acute promyelocytic leukemia Karishma K. Palande, Renee Beekman, Lotte E. van der Meeren, H. Berna Beverloo, Peter J. M. Valk, Ivo P. Touw
PLoS one. 2011 Jan 20;6(1):e16340.




The antioxidant peroxiredoxin (PRDX) protein family comprises 6 members, which are im-
plicated in a variety of cellular responses, including growth factor signal transduction. PRDX4 
resides in the endoplasmic reticulum (ER), where it locally controls oxidative stress by reduc-
ing H2O2 levels. We recently provided evidence for a regulatory function of PRDX4 in signal 
transduction from a myeloid growth factor receptor, the granulocyte colony-stimulating fac-
tor receptor (G-CSFR). Upon activation, the ligand-induced G-CSFR undergoes endocytosis 
and routes via the early endosomes where it physically interacts with ER-resident PRDX4. 
PRDX4 negatively regulates G-CSFR mediated signaling. Here, we investigated whether 
PRDX4 is affected in acute myeloid leukemia (AML); genomic alterations and expression 
levels of PRDX4 were investigated. We show that genomic abnormalities involving PRDX4 
are rare in AML. However, we find a strong reduction in PRDX4 expression levels in acute 
promyelocytic leukemia (APL) compared to normal promyelocytes and different molecular 
subtypes of AML. Subsequently, the possible role of DNA methylation and histone modifica-
tions in silencing of PRDX4 in APLs was investigated. We show that the reduced expression 
is not due to methylation of the CpG island in the promoter region of PRDX4 but correlates 
with increased trimethylation of histone 3 lysine residue 27 (H3K27me3) and lysine residue 
4 (H3K4me3) at the transcriptional start site (TSS) of PRDX4, indicative of a bivalent histone 
code involved in transcriptional silencing. These findings suggest that the control of G-CSF 
responses by the antioxidant protein PRDX4 may be perturbed in APL.




G-CSF induces the proliferation, survival and neutrophilic differentiation of myeloid pro-
genitor cells [1]. This response depends on the balanced activation and subsequent attenu-
ation of signaling pathways linked to the G-CSFR, which is to a major extent controlled by 
lysosomal routing of the activated G-CSFR complex [2-3]. Signal attenuation of the G-CSFR 
is compromised by mutations causing truncations in the cytoplasmic domain of the receptor, 
found in severe congenital neutropenia (SCN) patients showing disease progression to acute 
myeloid leukemia (AML) [4-6]. These truncated G-CSFR forms are defective in internaliza-
tion and lysosomal routing, which plays a major role in the abnormal signaling function of 
these receptor mutants. 
Another important feature of the G-CSFR truncation mutants is that their activation 
results in elevated levels of reactive oxygen species (ROS) relative to the wild type G-CSFR 
[7]. ROS have been shown to modulate growth factor signal transduction, due to inactiva-
tion of oxidation sensitive protein and lipid phosphatases [8-9]. Increased concentrations 
of intracellular ROS, however, have been implicated in DNA damage as well as in damage 
to proteins and lipids. Hence it is of importance to maintain steady state levels of ROS. 
PRDX4 is an antioxidant protein which resides in the endoplasmic reticulum. It is not only 
responsible for maintaining steady state levels of ROS but also for reactivation of oxidized 
phosphatases [10-11]. Our recent findings suggest that PRDX4 interacts with a C-terminal 
region of the G-CSFR, a region lacking in the truncated G-CSFR found in SCN/AML. PRDX4 
was shown to attenuate G-CSFR signaling dependent on the integrity of its redox active thiol 
group (Palande et al, manuscript submitted). Supporting a possible involvement of PRDX4 in 
leukemogenesis, a chromosomal translocation, t(X;21)(p22;q22) has been reported in a case 
of AML resulting in a PRDX4-RUNX1 fusion transcript [12].
We have investigated whether the PRDX4 locus is associated with translocations and 
mutations in AML and whether its expression levels are altered. We report that chromosomal 
translocations involving the PRDX4 locus are rare in AML. In addition, we did not detect 
single nucleotide variations in the PRDX4 coding region in a large panel of AML and MDS 
patients. On the other hand, we found that PRDX4 expression is significantly decreased in 
APL, a subset of leukemias that is characterized by hyper responsiveness to G-CSF [13]. 
Reduced PRDX4 expression in APL is associated with a bivalent histone methylation mark, 
i.e., the combination of repressive histone methylation mark H3K27me3 and the activating 
histone methylation mark H3K4me3, at the TSS of PRDX4 but not with DNA methylation of 
CpG islands in its promoter region. 





All human cell samples were obtained after written informed consent and stored anony-
mously in a biobank. The study was performed under the permission of the Institutional 
Review Board of the Erasmus MC, registration number MEC-2008-387. Preparation of leu-
kemia cell samples has been described previously [14]. Normal myeloblasts, promyelocytes 
and neutrophils were isolated from normal bone marrow samples using fluorescence acti-
vated cell sorting (FACS). Erythrocytes were removed prior to FACS sorting, by hypotonic 
lysis (15 min.), followed by a wash with phosphate buffer saline (PBS). The cells were then 
resuspended in PBS and incubated with fluorescent dye conjugated antibodies CD10-APC, 
CD11b-APC-Cy7, CD34-Pe-Cy7 and CD117-PE (Becton Dickinson, NJ) dead cells were 
excluded using a combination of forward and side scatter and DAPI staining. Cells were 
sorted with a FACSAria (Becton Dickinson, Becton Dickinson and Company, NJ) on the fol-
lowing criteria: CD34- and CD117+ for promyelocytes; CD34+ and CD117+ for myeloblasts; 
CD10+ and CD11b+ for neutrophils.
Mutation analysis of the PRDX4 coding region
A WAVE device (Transgenomics, Omaha, NE, USA) was used to screen for mutations in 
the PRDX4 coding region. cDNA from 113 AML and 65 MDS patients was analyzed. The 
coding region of PRDX4 was PCR amplified in 4 separate parts, the length of each part 
being approximately 300 base pairs with an overlap of at least 60 base pairs between two 
consecutive fragments. The first part of the PCR was amplified using primers PRDX4 F1 
(5’-CCAAGGGACGTGTTTCTGCG-3’) and primer PRDX4 R1 WAVE (5’-CTGGCTTG-
GAAATCTTCGC-3’). The second part was amplified using primers PRDX4 F2 WAVE 
(5’-GAGGAGTGCCACTTCTACGCG-3’) and PRDX4 R2 WAVE (5’-CTGTGAATCAA-
CAGAGCATG-3’). The third part of PRDX4 was amplified using primers PRDX4 F3 WAVE 
(5’-GGTTTTCTTCTTCTACCCACT-3’) and PRDX4 R3 WAVE (5’-CATTCAGAGTA-
ATTTGTCTTAG-3’). The last part of PRDX4 was amplified using primers PRDX4 F4 WAVE 
(5’-GGACTATGGTGTATACCTAG-3’) and PRDX4 R1 (5’-CCGTGAACTTTATTGAGA-
ACTTTC-3’).
fISh analysis
A locus-specific break apart FISH probeset was designed using the BAC clones CTD-2114P24 
(chrX: 23457583- 23659210) and CTD-2594J24 (chrX:23638596-23807502). Clone isolation 
and labeling were performed using biotin-16-dUTP and digoxigenin-11-dUTP (Roche 
Diagnostics Belgium, Vilvoorde, Belgium) according to the manufacturer’s protocol. The 
FISH analysis was performed as previously described on metaphase preparations.  For this, 
patient samples were cultured and harvested according to standard cytogenetic protocols. 
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Hybridized preparations were digitally imaged and analyzed using Isis (MetaSystems, 
Altlussheim, Germany). A minimum of 100 interphase nuclei and 5 metaphases were 
analyzed [15].
Gene expression analysis 
To determine expression of different peroxiredoxin family members (PRDX1-6), data of 439 
de novo AML and 22 APL samples were used [16]. For each gene, probe sets were determined 
and the average expression levels in AML and APL were calculated. Significant differences 
within these two groups were determined with a Wilcoxon test. Multiple testing correction 
was performed using the Benjamini-Hochberg algorithm. Probesets with an FDR below 
0.05 were considered to be differentially expressed in APL compared to AML. To examine a 
possible inverse correlation between expression of PRDX4 and TRAIL, Pearson correlation 
coefficients were calculated separately in the APL cases.
western blotting and antibodies
Cells were lysed in lysis buffer (20mM Tris HCl pH 8.0, 137mM NaCl, 10mM EDTA, 100mM 
NaF, 1% NP40, 10% glycerol, 2mM Na3VO4 and 1mM Pefablock SC). SDS-polyacrylamide 
gel electrophoresis was performed using precast 4-12% bis-Tris gradient gels (Invitrogen, 
Breda, the Netherlands). Prdx4 mouse monoclonal antibody was purchased from Abcam, 
(Cambridge, UK), β-actin antibody from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
bisulfite sequencing
Bisulfite treatment of genomic DNA from APL or AML samples was performed using 
the EpiTect bisulphite kit (Qiagen, Hilden, Germany). PCR was performed on bisulfite 
treated DNA using methylation insensitive primers PRDX4 bisulfite seq Fw1 (5’-TT-
GTTTTTATAGAGTTGGGTAA-3’) and PRDX4 bisulfite seq Rv1 (5’-AAACCTCTCCTC-
TATCTCC-3’). A nested PCR was performed on this PCR product using methylation 
insensitive primers PRDX4 bisulfite seq Fw2 (5’- TAAATGTAGGTTTGGGATGG-3’) and 
PRDX4 bisulfite seq Rv2 (5’- CCAACCCTACACAACTCCAA-3’). For sequencing, the PCR 
product was sub-cloned into TA cloning vector (Invitrogen, Breda, the Netherlands). DNA 
was isolated from individual colonies and sequenced using the M13Fw (5’-GTAAAACGAC-
GGCCAG-3’) and the M13Rv (5’-CAGGAAACAGCTATGAC-3’) primers.
Chromatin isolation 
Ten million cells were suspended in 10 ml culture medium and cross-linked with 1% form-
aldehyde for 10 min at RT. The reaction was quenched with 130 mM glycine. Cells were 
washed twice with cold PBS and subsequently incubated on ice for 10 min with cold nuclei 
lysis buffer (50 mM Tris HCl, 10mM EDTA, 1% SDS) to which 1 mM protease inhibitors 
(Sigmafast, Sigma Aldrich, St Louis, MO) and 4 mM PMSF (Sigma Aldrich, St Louis, MO) 
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was freshly added. Lysed cells were subjected to 6 cycles of sonication for 20 sec to obtain 
fragments of 200-1000 bp (Sanyo Soniprep 150). After centrifugation (10 minutes, 10.000 g) 
at 4 ºC to remove cell debris, the chromatin-containing supernatant fraction was pre-cleared 
by incubation with 50μg pre-immune serum (IgG from rabbit serum I8140, Sigma-Aldrich, 
St Louis, MO) for 30 min at 4 ºC followed by addition of 100μl protein A magnetic beads 
(Invitrogen, Breda, the Netherlands) for 30 min at RT. 
Chromatin immunoprecipitation (ChIP)
For immunoprecipitation, protein A dynabeads (Invitrogen, Breda, the Netherlands) were 
pre-incubated with antibodies against H3K27me3 (07-449, Upstate Biotechnology Inc, 
Charlottesville, VA) or IgG pre-immune serum as control (Sigma Aldrich, St Louis, MO). 
Twenty-five μl beads and 2.5μg antibody were incubated for 30 min at room temperature. 
Beads pre-coupled to respective antibodies were then added to the pre-cleared chromatin 
and incubated for 2 hrs at 4 ºC. Magnetic beads containing the chromatin complexes were 
collected with a magnet and sequentially washed (5x) with 500 μl: 1x low salt wash for 1 
min (20 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1mM PMSF), 1x high 
salt wash for 1 min (20 mM Tris-HCl, 500 mM NaCl, 0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 1 mM PMSF), 1x LiCl wash for 5 min (10 mM Tris-HCl, 0.25M LiCl, 1 mM EDTA, 
1% IGEPAL, 1% deoxycholate, 1 mM PMSF) and 2x TE buffer for 1 min each (10 mM Tris 
HCl, 1 mM EDTA). ChIP samples were eluted with 200 μl elution buffer (25 mM Tris HCl, 
10 mM EDTA, 0.5 % SDS) at 65 ºC for one hr, subsequently 3.75mM NaCl was added and 
incubated overnight at 65ºC to reverse the cross-linking. After de-cross-linking, 2.4μg pro-
teinase K (Roche, Basel, Switzerland) was added for protein digestion. DNA was purified 
using a QIAquick PCR purification kit (Qiagen, Hilden, Germany). For PML-RARα ChIP 
experiments, HEK cells were transiently transfected with FLAG-tagged PML-RAR-pCMV 
or empty vector (ev-pCMV) constructs [24]. Chromatin isolation and precipitation was 
performed as described [24].
Quantitative PCR of ChIP-enriched sequences was performed using SYBR Green PCR Mas-
ter Mix (Applied Biosystems, Weiterstadt, Germany). The MYT1 gene served as a positive 
control in H3K27me3 ChIP [17]. For PRDX4, a primer set for the predicted TSS was used: Fw 
(5’-CAAATGCAGGCTTGGGATGG-3’) and Rv (5’-CAGCGCCTCCATGACCACG-3’). 
For the region 1kb downstream from the TSS: Fw (CAGGAATGACACGTCAGACG) and 
Rv (5’-CACTGAATACTGGCATGGAAC-3’); For the region 5kb downstream from the 
TSS: Fw (5’- GTTATGGTTATTGTGGGGTTTC-3’) and Rv (5’-GACATAACTCTTTTTG-
GTCTCTTC-3’). RARβ primers used were the same as described in [24].




Genetic abnormalities affecting the PRDX4 coding region are rare in MdS and aML
Previously, a case of AML with a t(X;21)(p22;q22) has been reported in which the PRDX4 
gene located on Xp22 was fused to RUNX1 at 21q22, resulting in a RUNX1-PRDX4 fusion 
transcript [12]. In a cohort of AML and MDS patients karyotypically analyzed in our institu-
tion between 1990 and 2008, we found 9 cases with chromosomal abnormalities involving 
Xp21/p22 by standard banding techniques. These cases were further studied for possible 
rearrangements in the PRDX4 locus using FISH with a PRDX4 break apart probeset, but 
no translocations, deletions or other gross rearrangements were detected. Subsequently, we 
screened cDNA from 65 MDS patients and 113 AML patients for possible mutations or poly-
morphisms, but no mutations in the PRDX4 coding region were detected in these samples. 
Thus, our data confirms that genomic aberrations affecting the PRDX4 coding region are rare 
in MDS/AML and so far confined to the one reported case [12]. 
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figure 1: Expression of PRDX transcripts in aML and aPL
(a) Graphical representation of expression of PRDX family members in APL patients clustered based on expression 
of ~2000 genes as described [14]. Cluster 12 is exclusively formed by APL patients, as indicated by the red bars indi-
cating the presence of t(15;17). Cluster 11 comprises AML patients with normal karyotype and an underlying NPM1 
mutation. Cluster 13 is formed by AML patients with t(8;21). Histograms represent MAS5-normalized expression 
values. (b) Expression levels of the peroxiredoxin gene family in APL (n=22) were compared to transcript levels 
in AML (n=439). Significant differences were calculated using a Wilcoxon test. * = p-value < 0.001, ** = p-value 
<0.0001. (C) APLs are not associated with high expression of TRAIL ligand excluding the possibility that low expres-
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PRdx4 is down regulated in aPL
Next, we analyzed PRDX4 expression levels in 461 myeloid leukemia patients measured 
on gene expression arrays [16]. In the majority of APL patients, PRDX4 levels are below 
detection levels; on average, PRDX4 transcript levels were 4 to 5 times lower in APL, rela-
tive to other AML samples (Figure 1A and 1B). In contrast, expression of the other PRDX 
family members was not (PRDX1, 2, 5 and 6) or only marginally (PRDX3) reduced in the 
APL patient cluster (Figure 1A and B). A recent study showed that TNFα-related Apoptosis 
Inducing Ligand (TRAIL) suppresses the expression of PRDX4 [18]. We therefore first inves-
tigated whether low levels of PRDX4 expression in APL are associated with high expression 
of TRAIL, but we did not find evidence for such an inverse correlation (Pearson correlation 
coefficient 0.26-0.35 for 3 different TRAIL probe set comparisons, figure 1C). Western blot 
analysis showed that the PRDX4 protein, while readily detectable in AML blast cells with 
high transcript levels, is low/ undetectable in APL cells correlating with the gene expression 
profiling data (Figure 2A). In contrast, PRDX4 protein levels were not reduced in normal 
bone marrow-derived myeloblasts, promyelocytes and myelocytes (Figure 2B, upper panel), 
suggesting that the down regulation of PRDX4 is specific for leukemic promyelocytes. The 
purity of the sorted fractions of cells used for Western blotting as mentioned above was as-
sessed using cytospins of the individual fractions stained with May Grünwald Giemsa (Figure 
2B, lower panel). 




figure 2: Reduced PRdx4 protein levels in aPL  
(a) Lysates of APL and AML samples were analyzed for PRDX4 protein levels. Because human PRDX4 gene is 
located on the X-chromosome, male samples and female samples were compared with male and female AML control 
samples respectively to rule out the possibility of X-inactivation involvement. Patient number followed by F indicates 
female sample while patient number followed by M indicates male sample. 
A
B
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(b) upper panel: Western blot analysis of PRDX4 expression in different normal bone marrow fractions (myelo-
blasts, promyelocytes, neutrophils). Lower panel: Micrographs of May Grunwald Giemsa stained fractions of cells 
used for Western blotting.
Reduced PRDX4 expression in aPL is not due to dNa methylation of CpG islands in the 
PRDX4 promoter 
PML-RARα recruits DNA methyltransferases such as DNMT1 and DNMT3a and is thereby 
potentially able to methylate CpG islands in target genes, leading to transcriptional silencing 
[19]. We asked whether PRDX4 expression in APLs might be silenced by DNA methylation. 
Because PRDX4 is located on the X chromosome, one allele is methylated in female cells. 
CpG methylation on both alleles in female samples or on one allele in the male APL samples 
was not observed (data not shown). Thus, no evidence was obtained indicating that DNA 
methylation of CpG islands within the promoter region contributes to silencing of PRDX4 
in APL cells. 
aPL cells have increased levels of h3K27me3 and h3K4me3 at the TSS of PRDX4 
PML-RARα recruits the polycomb repressor complex 2 (PRC2) that contains EZH2 as a 
major effector protein [20]. EZH2 represses gene expression through H3K27me3, leading 
to an inactive chromatin configuration [21]. ChIPs performed on primary APL cells showed 
an increased occupation of H3K27me3 at the TSS of PRDX4 (Figure 3A), which was not 
observed in AML samples expressing PRDX4. Unlike the H3K27me3 ChIPs, results from 
H3K4me3 ChIPs showed occupation of the TSS of PRDX4 by the H3K4me3 methylation 
mark in both, APLs as well as AMLs (Figure 3B). 
To study a possible direct involvement of PML-RARα in PRDX4 silencing, we performed 
ChIP experiments on HEK cells expressing a FLAG-tagged form of PML-RARα. This set 
up was chosen because of a lack of antibodies suitable for PML-RARα specific ChIP. The 
RARβ locus was used as a positive control in these experiments [24]. PML-RARα interacted 
with the TSS and even more strongly with a region 1kb downstream of the TSS of PRDX4 
as compared to the IgG controls (Figure 4). In contrast, the region 5kb downstream of the 
PRDX4 TSS showed no binding of PML-RARα. 
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figure 3: bivalent h3K27me3 and h3K4me3 marks are present at the TSS of PRDX4 
ChIP using αH3K27me3 and an IgG control (A) and αH3K4me3 and an IgG control (B) showing an enrich-
ment of both H3K27me3 and H3K4me3 at the TSS of PRDX4 in APL cells. To rule out a possible involvement of 
X-inactivation, and thereby H3K27me3, in silencing of PRDX4 expression, male APL samples are compared to a 
male AML control and female APL samples are compared to a female AML control.
Figure 3
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figure 4: PML-RaRα binds the promoter of PRDX4
Chromatin IPs on HEK cells expressing FLAG-tagged PML-RARα fusion protein using anti-FLAG and IgG control 
antibodies. Binding of PML-RAR occurs to the TSS of PRDX4 and a region 1kb (1kb) of the TSS but not to a region 
5kb downstream of the TSS (+5kb). RARβ is used as a positive control. 
Figure 4




The major finding reported here is that expression of the antioxidant protein PRDX4 is 
repressed in t(15;17) APL harboring the PML-RARα fusion protein. Our data indicate that 
transcriptional regulation of PRDX4 is perturbed in APLs because normal promyelocytes 
do not show reduced PRDX4 protein levels. This reduced expression is linked to a bivalent 
histone mark, i.e., increased H3K27me3 and H3K4me3, at the TSS of PRDX4. Bivalent 
histone marks provide a switch mechanism shown to be involved in transcriptional regula-
tion of developmental genes; loss of the H3K27me3 mark leads to transcriptional activation 
whereas loss of H3K4me3 results in permanent silencing [22]. Our data suggest that reduced 
PRDX4 expression in APLs is caused by maintenance of H3K27me3, which perturbs the 
bivalent switch. We hypothesized that PML-RARα might be involved in repressing PRDX4 
expression, especially because PML-RARα recruits the polycomb repressor complex (PRC2) 
that contains the histone methyltransferase EZH2 responsible for H3K27me3 [20]. Although 
PML-RARα indeed binds in the vicinity (1kb downstream) of the PRDX4 TSS, further studies 
are required to support the direct involvement of PML-RARα in PRDX4 downregulation. 
Wild type retinoic acid receptors (RARs) are known to bind to specific DNA sequences 
called RA responsive elements (RAREs) and are able to repress transcription by recruiting 
co-repressor complexes such as SMRT/NCoR/ HDAC [23]. The promoter region of PRDX4 
however does not contain any retinoic acid responsive element (RARE) that may be bound 
by RARα/RXR directly. Another mechanism shown to be involved in suppression of genes 
via PML-RARα is the modulation of the activity of Sp1 target genes via binding to the tran-
scription factor Sp1 [24]. Six Sp1 sites are present within the region of -1kb to +1kb of the 
TSS of PRDX4, to which the PML-RARα fusion protein may bind in a RARE independent 
manner [24]. 
To support the hypothesis of PML-RARα-mediated recruitment of PRC2/EZH2 to the 
PRDX4 TSS, leading to H3K27me3 repression of the gene, we have attempted to restore 
Prdx4 expression in primary APL. To achieve this, APL cells were incubated with (combina-
tions of) pharmacological compounds that included the “de-repressing” agents ATRA, the 
histone deacetylase inhibitor valproic acid and EZH2 inhibitor DZNep, which reduces EZH2 
protein levels and thereby the level of H3K27me3 at transcriptional start sites of certain genes 
[25]. However, down regulation of EZH2 by DZNep, as previously shown by Jiang et al in 
colorectal cancer cells, was not seen in the APL samples used in our studies. Further studies 
are required to support a direct involvement of PML-RARα in PRDX4 down regulation. 
Irrespective of the molecular mechanism of transcriptional silencing, a lack of PRDX4 
may have a major impact on cellular responses of myeloid cells and contribute to leukemo-
genesis. PRDX4 resides mainly in the endoplasmic reticulum (ER), where it is thought to 
neutralize the oxidizing effects of locally produced ROS [26]. This would keep for instance 
oxidation sensitive ER-resident phosphatases, such as protein tyrosine phosphatase 1b 
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(PTP1B), in an active state. PTP1B has been shown to play a role in down modulation of G-
CSFR mediated signaling by dephosphorylating Jak2, Stat3 and the tyrosines of the G-CSFR 
(Palande et al, manuscript submitted). Predictably, loss of PRDX4 could lead to a reduction 
of phosphatase activity, providing an explanation for the increased responsiveness of APL 
clonogenic precursors to G-CSF. 
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Thioredoxin-interacting protein (TXNIP) is involved in reactive oxygen species-induced 
stress responses. In a screen for novel disease genes in murine leukemia virus (MLV)-
induced mouse leukemias, we identified Txnip as a frequent target for proviral integration. 
Ectopic TXNIP expression inhibited the proliferation of myeloid progenitor cells. TXNIP 
transcript and protein levels were significantly elevated in human AML blasts of certain pa-
tients, particularly those harboring translocation t(8;21). Nucleotide sequencing revealed no 
abnormalities in the TXNIP coding region in AML. These findings suggest that deregulated 
TXNIP expression contributes to MLV-induced murine leukemia as well as human AML.




Acute myeloid leukemia (AML) is characterized by the uncontrolled outgrowth of malignant 
immature myeloid cells in the bone marrow (BM) and peripheral blood. It is now generally 
accepted that leukemogenesis is a multistep process, requiring defects in multiple regulatory 
genes that may be caused by chromosomal translocations and deletions or by mutations. 
In addition, increasing evidence suggests that inadequate control of intracellular levels of 
reactive oxygen species (ROS) may contribute to AML development, mechanisms being im-
plicated including different anti-oxidant systems, such as superoxide dismutase, glutathione 
and peroxiredoxin/thioredoxin systems [1-2]. Thioredoxin-interacting protein (TXNIP) is 
a stress response protein implicated in the control of cancer [3]. Based on its growth sup-
pressive effects and the finding that TXNIP expression is down regulated in certain tumors, 
TXNIP has been classified as a tumor suppressor [3]. TXNIP is also known as Vitamin D 
Upregulated Protein 1 [4]. In a retroviral screen with Graffi 1.4 (Gr-1.4) MLV, we previously 
found Txnip as a target for viral integration in myeloid leukemia [5]. This finding suggests a 
role for TXNIP in murine and human leukemias. To address this hypothesis, we mapped the 
provirus integrations in Txnip in Gr-1.4 and CasBrM MLV-induced leukemias and studied 
the consequences of these integrations for the regulation of Txnip transcription. In addition, 
we have studied the effects of enforced expression of Txnip in myeloid 32D cells and primary 
BM progenitors. Finally, we have performed an extensive mutation analysis of the human 
TXNIP gene and investigated TXNIP protein levels in human AML samples.
MaTERIaL aNd METhOdS
Locus specific nested PCR
The PCR strategy and sequence protocols to identify provirus integrations in specific loci in 
mouse leukemia cells has been described in detail [5-6].
PCR primers and probes
Primers and probes used in this study are listed in supplementary Table 1.
Cell culture and retroviral transduction
Txnip cDNA was amplified with primers SmaIF and SmaIR and cloned in pBABE and R780 
(SF91-I-eGFP-PRE, a kind gift of Dr. C. Stocking) using standard procedures. BM cells were 
harvested from the femurs and tibiae of 8 to 12 weeks old FVB mice, cultured and co-infected 
with equal amounts of BABE virus together with recombinant R780-Txnip or empty R780 
virus as previously described [6]. EGFP expression was measured by flow cytometry. Equiva-
lent numbers of GFP positive cells were plated in triplicate in methocultTM M3231 (Stem 
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Cell Technologies Inc, Vancouver, Canada) and selected with puromycin (1.5 µg/ml). The 
cells were plated with human (h) granulocyte colony stimulating factor (GCSF) (10 ng/ml), 
granulocyte macrophage (GM)-CSF (20 U/mL), or with a cocktail of murine (m) interleu-
kin-3 (mIL-3) (10 ng/mL), hIL-6 (100 ng/mL), and stem cell factor (mSCF) (100 ng/mL).
Promoter constructs
To generate pGL3-V5, a 1448 nucleotide region upstream of the major ATG of Txnip was 
amplified by PCR using primers F1 and R2, and inserted into the MluI and BglII sites of 
pGL3-basic (Promega, Leiden, The Netherlands). The 3’UTR of Txnip was amplified with 
primers F3 and R5, and ligated into the XbaI site of pGL3. The Gr-1.4 LTR was PCR ampli-
fied with primers Graffi-LTR1 and Graffi-LTR2 and inserted into the DraI site in the Txnip 
promoter region and in the NcoI site of the Txnip 3’UTR.
Luciferase reporter assay
HEK293 were seeded and transfected by standard CaPO4 methods with pcDNA3.1/mycHis/
LacZ (Invitrogen, The Netherlands), encoding LacZ as an internal control. Cells were lysed 
and assayed as described [6].
human aML samples
Human AML samples were obtained following informed consent and prepared as described [7].
western blotting
Lysates of BM blast cells from AML patients [7] were prepared and subjected to Western 
blotting as described [6] using mouse monoclonal anti-TXNIP1 antibody Yat315 (a kind gift 
of Drs. Junji Yodoi and Hiroshi Masutani [8] to visualize TXNIP and Goat anti-ACTIN (I-19; 
Santa Cruz Biotechnology, CA) as control.
TxNIP sequence analysis
TXNIP cDNA from AML patients and normal individuals was amplified with primers 
TXNIP-forward-2 and TXNIP-reverse-2. For sequencing, the same primers were used in 
addition to primer seq-R1 and seq-R2. SNP analysis was performed using probes VIC and 
FAM (Applied Biosystems) as described previously [9].




Identification of virus integration sites in Txnip
The first two Gr-1.4 integration sites in the Txnip locus identified by inverse PCR were lo-
cated 1.1 kb upstream of the transcriptional start site and 0.35 kb downstream of Txnip [5]. 
To determine the frequency of integrations in these regions, we performed directed PCR on 
genomic DNA isolated from 14 independent leukemias. Gr-1.4 integration sites in the Txnip 
locus are mainly located between 0.2 to 1.8 kb upstream of the transcriptional start site, or 
dispersed within the 3’UTR of exon 8. All samples contained multiple virus integrations in 
the 5’ promoter region or in the 3’ UTR of Txnip and occurred in both orientations with 
equal frequencies (Fig. 1A and B). Directed PCR on genomic DNA from 24 CasBrM-induced 
myeloid leukemias gave comparable results, but with a lower frequency (58%) (data not 
shown). Interestingly, retroviral insertions in the Txnip locus were not found in B- and T-cell 
leukemia screens, except for one mapped integration in the AkxD leukemia model (http://
rtcgd.abcc.ncifcrf.gov), suggesting a specific involvement in murine myeloid leukemia.
Integrations of Gr-1.4 LTR deregulates Txnip expression
Integrations in the 5’ region are thought to increase the expression of the flanking gene 
through the transcriptional enhancer activity of the LTR. In agreement with this, insertion 
of Gr-1.4 LTR sequences in the 5’ region resulted in a 2-fold increased activity in a luciferase 
reporter assay (Fig. 1D and E). LTR sequences in the 3’ region had a weaker effect. Possibly, 3’ 
virus integrations interfere with mRNA stability or normal regulation of translation. Finally, 
we observed elevated Txnip protein levels in some of the MLV-induced leukemia samples 
compared to normal BM in Western blot analysis (Figure 1C). Together, these data suggest 
that virus insertions in the Txnip locus result in enhanced protein expression.
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figure 1. viral integrations in Txnip
(a) Virus integrations in Gr-1.4 MLV-induced leukemias in the 5’ UTR of Txnip. (b) Virus integrations in Gr-1.4 
MLV-induced leukemias in the 3’ UTR of Txnip. Data are compiled from 14 leukemia samples. (C) Western blot 
analysis of MLV-induced leukemia samples and normal bone marrow (NBM) with anti-Txnip antibodies (Yat315). 
Actin was stained for loading control. Txnip expression normalized to actin levels and relative to NBM is plotted. 
(d) Reporter plasmids containing different promoter and 3’UTR sequences were generated as depicted. (E) Luciferase 
assay results in HEK293 cells. Cells were transfected with the indicated reporter plasmids and a LacZ plasmid as an 
internal control. Forty hours post transfection, cells were lysed and assayed for luciferase activity. Luciferase activity 
values were normalized against β-galactosidase activity. Values are the mean of three independent experiments, each 
performed in triplicate. Error bars represent standard deviation. (f) CFU assay of primary BM progenitor cells fol-
lowing transduction with R780-Txnip and R780 control virus (EV). Equivalent numbers of GFP-positive BM cells 
were plated in triplicate at densities of 105 cells (CFU-G), 5x104 cells (CFU-GM), or 104 cells (CFU-IL-3, IL-6, SCF) 
per dish in 1 ml methylcellulose medium containing G-CSF, GMCSF, or a cocktail of Il-3, Il-6 and SCF. Colonies 
of more than 50 cells were counted on day 7 of culture. Values are the mean of two independent experiments, each 
performed in triplicate. Error bars represent standard deviation.
Ectopic expression of Txnip inhibits primary bM cell growth
Next, we investigated how increased Txnip expression affects the outgrowth of primary BM 
progenitors. To this end, we retrovirally transduced mouse BM cells with R780-FLAG-Txnip 
or control virus and plated these cells in colony assays with different growth factors. Colony 
formation by Txnip overexpressing BM cells was significantly reduced under all stimulatory 
conditions tested (Fig. 1F). However, ectopic Txnip expression did not affect the differen-
tiation, nor did it increase apoptosis (data not shown). Similar results were observed in the 
myeloid cell line 32D (data not shown). These data suggest that elevated Txnip expression 
predominantly causes a growth arrest, rather than cell death in myeloid progenitor cells. 
Similar findings in 293 cells have been reported previously [4].
TxNIP expression in human aML
To extend the observations in mice to patients, we studied TXNIP expression in purified 
human AML samples [7, 10]. We determined TXNIP transcript levels in different classes of 
adult and pediatric AML patients [7, 10]. Differential expression between classes of patients 
was performed for all probe sets on the Affymetrix HGU133A GeneChip using significance 
analysis of microarrays (SAM) [11]. This method tests a class of AML patients for signifi-
cantly differentially expressed genes compared to a second class of AML patients, in this case 
the remaining samples. TXNIP mRNA levels were lower in cluster 6 compared to the average 
of all 285 AML samples measured. In contrast, TXNIP expression was significantly higher 
by SAM analyses in cluster 13 of human adult AML (fold change value of 1.53) and in a 
cluster of pediatric AML (fold change value of 1.83), both characterized by t(8;21) (Figure 
2A). Quantitative PCR confirmed expression values determined by micro array analysis (data 
not shown). Next, we examined TXNIP protein expression by Western blot in 42 purified 
human AML blast samples [7] compared to normal CD34+ blast samples. Representative 
Western blots are shown in Figure 2B. In 33 cases, TXNIP protein levels were significantly 
elevated compared to normal CD34+cells. Notably, increased TXNIP protein levels were not 
exclusively observed in AML t(8;21) cases, suggesting that post transcriptional mechanisms 
may also contribute to elevated TXNIP expression.




figure 2. TxNIP levels in human aML samples
(a) Level of TXNIP mRNA expression in 285 human AML samples. The 16 clusters with molecular characteristics 
in a cohort of 285 AML patients have been published [7] and are depicted on the X-axis. Molecular characteristics 
associated with the clusters are: cluster 1: t(11q23), 2: FLT3-ITD, 3: FLT3ITD, 4: CEBPa mutations, 6: FLT3-ITD, 9: 
inv(16), 10: Evi-1, 12: t(15;17), 13: t(8;21), 15: CEBPα mutations, 16: t(11q23). TXNIP mRNA expression was found 
significantly lower (as indicated by *) or higher (**) by SAM analyses in clusters of leukemia. Probe sets of TXNIP 
were considered to be differentially expressed when Fold Change was over 1.5 or under 0.67, score was over 4 or less 
than 4, and a q-value less then 5%, where False Discovery Rate was less than 5%. (b) Western blot analysis of human 
AML samples, HL60 and CD34+ cells with monoclonal anti-TXNIP antibodies. Actin was stained for loading con-
trol. TXNIP expression normalized to actin levels and relative to normal CD34+ cells is plotted.
Screening for TXNIP mutations in aML
To investigate whether mutations in TXNIP frequently occur in human AML, we sequenced 
the entire cDNA from leukemic blasts of 270 patients. Other than some rare nucleotide 
changes, one of which appeared to be a relatively infrequent polymorphism at nucleotide 
position 741C→T, in 7 out of 270 AML cases compared to 4 out of 671 in normal controls 
(p=0.0169), no changes in the TXNIP coding region were found (Table 1). This excludes the 








In this paper, we have identified Txnip as a common target of viral integrations in mouse 
leukemia and shown that TXNIP transcript and protein levels are elevated in a significant 
proportion of human AML cases. The key question that remains is how increased TXNIP 
levels contribute to leukemic cell growth. By interacting with thioredoxin (TRX), TXNIP 
causes the release of active ASK1, a stress-related serine threonine kinase that activates JNK. 
Although thus far mainly linked with apoptosis induction [12], a recent study indicates that 
this pathway also controls a G1-S cell cycle checkpoint, leading to growth arrest without 
detectable apoptosis [13]. This provides a plausible explanation for the observed inhibitory 
effects of TXNIP on normal bone marrow progenitors. Because TRX is a key anti-oxidant 
protein in the NADPH oxidase system, inhibition of TRX by TXNIP will result in increased 
levels of intracellular ROS [14]. This will predictably not only cause sustained oxidized 
protein and DNA damage, but also lead to increased growth and survival stimulatory ac-
tivities of growth factors, through down modulation of critical phosphatases, such as the 
PI3K antagonist PTEN, by oxidation of catalytic sites [15]. Eventually, sustained increased 
cellular ROS levels will contribute to genomic instability in hematopoietic precursors that 
may lead to transformation and clonal outgrowth of myeloid precursor cells, resulting in 
development of leukemia [16]. Deregulation of redox-controlled gene expression thus may 
be a frequent event in the pathogenesis of myeloid leukemia. For leukemic transformation 
of myeloid progenitor cells via TXNIP induced ROS levels, additional hits, e.g., disrupting 
pro- or activating anti-apoptotic genes, would be needed. Further understanding of pathways 
controlled by TXNIP during myelopoiesis and a more detailed understanding of the signal-
ing pathways influenced by TXNIP in hematopoietic cells in normal state and during cellular 
stresses will be required to understand whether and how increased TXNIP levels contribute 
to the development of human AML.
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5.1.1 Ptp1b and Prdx4 negatively regulate G-CSfR signaling
Endocytosis of receptors exposes the receptors to different PTPs, localized within different 
sub-cellular compartments, which contribute to signal termination. Although several phos-
phatases (Shp1, Shp2 and SHIP1) attenuate G-CSFR mediated signaling, these PTPs do not 
dephosphorylate the G-CSFR tyrosines. Dephosphorylation of receptor tyrosines ensures 
turn-off of signaling.
Studies performed using immortalized MEFs derived from Ptp1b-/- mice have already 
shown that Ptp1b plays a critical role in dephosphorylation of tyrosines of several receptors 
[1-3]. Our findings with respect to the role of Ptp1b in G-CSFR signal regulation are in agree-
ment with those showing regulation of leptin receptor signaling by Ptp1b. In the context of 
the leptin receptor, Ptp1b was shown to physically interact with Jak2 and negatively regulate 
the activity of both, Jak2 and Stat3 [4-5]. Our findings clearly demonstrate the role of Ptp1b 
in inhibition of G-CSFR signaling and proliferation (Chapter 2). Phosphorylated tyrosines 
of G-CSFR, p-Jak2, p-Stat3 and p-Prdx4 were found to be targets of Ptp1b with respect to 
G-CSFR signaling. However, because activation of Stat3 is dependent on p-Jak2, it cannot 
be concluded whether p-Stat3 is a direct target of Ptp1b or whether Ptp1b regulates p-Stat3 
levels indirectly by regulation of p-Jak2 levels. 
Loss of either Prdx4 or Ptp1b in bone marrow cells leads to increased colony formation in 
response to G-CSF and both Prdx4 deficient and Ptp1b deficient fibroblasts show prolonged 
Stat3 activation upon stimulation with G-CSF. These findings suggest that Prdx4 and Ptp1b 
act in the same signaling pathway. We also found that the levels of phosphorylation of Prdx4 
are higher in MEFs lacking Ptp1b. This suggests that Ptp1b positively regulates the activity of 
Prdx4 by dephosphorylation. Prdx4 in turn could reduce the levels of ROS produced upon 
G-CSFR activation and also reactivate Ptp1b by reducing the cysteine in its catalytic site 
(Figure 1). 
The carboxyl terminus of the G-CSFR binds several proteins that are responsible for 
signal down modulation. Prdx4 and Ptp1b bind to the G-CSFR and inhibit G-CSFR signal-
ing. We reported that the antioxidant, Prdx4 binds to the C-terminus of the G-CSFR where 
it inhibits signaling via the G-CSFR depending on the presence of cysteines in its catalytic 
site/s. Such a mechanism has only been reported for the PDGFR so far [6]. Knockdown of 
Prdx2 resulted in increased activation of the PDGFR. Amongst the peroxiredoxin family 
members, only Prdx4 interacted with the G-CSFR and the most N-terminal region of Prdx4 
was involved in interaction with the G-CSFR. Prdx2 and Prdx4 proteins are more than 70% 
identical and only differ in the additional 73 amino acids present in the N-terminus of Prdx4. 
Prdx2 however was not found to interact with G-CSFR in MAPPIT assays indicating that 
the N-terminal of Prdx4 might be critical for interaction with G-CSFR. Prdx4 could act as 
a tether whereby it could bring G-CSFR in the close proximity of Ptp1b, thereby allowing 
Ptp1b to dephosphorylate G-CSFR. 
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figure 1: Positive feed back loop at the ER
Specifically at the ER, Ptp1b and Prdx4 down modulate G-CSFR signaling. The oxidized Prdx4 is reduced by Trx. 
Ptp1b dephosphorylates Prdx4 thereby activating it. Ptp1b also dephosphorylates tyrosines of the G-CSFR and also 
Jak2 and Stat3 thereby terminating signaling.  Prdx4 reduces levels of ROS and also reactivates oxidized Ptp1b. 
5.1.2 dynamics and mechanisms of receptor dephosphorylation 
The sub-cellular localization of Prdx4 is a much debated topic. The N-terminus of Prdx4 
contains a signal peptide. Some reports show that Prdx4 is localized in the lumen of the ER 
while others show that Prdx4 is present on the surface of the ER [7-9]. Besides, the phospha-
tase Ptp1b is also localized to the surface of the ER [10-11]. Only under certain circumstances 
Ptp1b can be released from the ER [12]. 
It is believed that dephosphorylation of receptors precedes their degradation. However it 
is unknown whether dephosphorylation is a prerequisite for degradation [13]. Upon endo-
cytosis, the receptors route via the late endosomes to the lysosomes where they are degraded. 
This pathway raises questions regarding how an ER-localized phosphatase dephosphorylates 
tyrosines of receptors present at the plasma membrane or in endocytotic vesicles. 
The earlier concept of Ptp1b interacting only with newly synthesized receptors was 
proven incorrect by the findings which showed interaction of Ptp1b with activated PDGF 
and EGF receptors [13]. Upon stimulation with growth factors like EGF and PDGF, Ptp1b 
was found to cluster in regions on the face of the ER [13-14]. Using a FRET based approach 
Figure 1
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it was shown that the activated EGFR routed via the ER where it interacted with the Ptp1b 
[13]. As proposed by the pit stop model, after a ‘pit-stop’ at the ER, where the receptors are 
dephosphorylated, the EGFR proceeded to the lysosomes where they were degraded [15]. 
More recent evidence suggests that the interaction between ER-localized Ptp1b and 
endosomes containing EGFR occurs when the membranes of these two compartments come 
in contact with each other [16]. Two hours after stimulation with EGF, the cells expressing 
the catalytically inactive, Ptp1b substrate trapping mutant showed accumulation of EGFR in 
MVBs while the non-transfected cells showed presence of EGFR in the lysosomes. In cells 
expressing the EGFR, stimulation with EGF leads to the formation of internal vesicles within 
MVBs. Expression of substrate trapping mutant of Ptp1b leads to a block in formation of 
these internal vesicles within MVBs. Although overexpression of Ptp1b leads to accelerated 
degradation of EGFR, knocking down Ptp1b expression has no effect on the lysosomal rout-
ing of EGFR. The rapid degradation of EGFRs in Ptp1b overexpression conditions could 
be explained by the fact that other proteins of the endosomal sorting complex (ESCRT) 
machinery could also be targets of Ptp1b.  
Indeed, STAM2, a part of the ESCRT machinery, required for targeting activated recep-
tors for lysosomal degradation, was also found to be a target of Ptp1b [17]. Ptp1b interacts 
with STAM2 localized in early endosomes and dephosphorylates tyrosines of STAM2. While 
the phosphorylation defective mutant of STAM2 displayed prolonged co-localization in EGF 
positive endosomes and did not route to lysosomes, no effect was observed on the trafficking 
of EGFRs. Loss of Ptp1b expression may result in hyper-phosphorylation of STAM2 leading 
to dissociation of STAM2 from ubiquitinated EGFRs thereby preventing their trafficking into 
MVBs. Whether dephosphorylation of STAM2 affects its binding affinity for ubiquitinated 
substrates remains unknown. These findings raise the hypothesis of Ptp1b being a controller 
of the receptor trafficking process. Based on data from Stuible et. al. [17], it can be conceived 
that Ptp1b also regulates routing of G-CSFR. 
Spatial segregation of Ptp1b limits its activity. Ptp1b is retained in a low activity state 
[14] mostly by the Nox4 mediated ROS production in the ER [18]. The role of Ptp1b in 
dephosphorylation of receptors might be secondary to its role in controlling receptor traffick-
ing. Most of the targets of Ptp1b are known to recycle back to the plasma membrane upon 
dephosphorylation and ligand dissociation [19-20]. However, G-CSFRs do not recycle back 
to the plasma membrane after ligand dissociation [21]. Although the role of Ptp1b in negative 
regulation of G-CSFR is clear, the question still remains as to whether dephosphorylation is 
a prerequisite for degradation. Activity of other proteins like STAM2, involved in receptor 
trafficking could be regulated by phosphorylation/ dephosphorylation. These proteins could 
be targets of Ptp1b. Ptp1b could indirectly control G-CSFR trafficking by regulating the activ-
ity of these proteins. 
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figure 2: Spatio-temporal regulation of G-CSfR signaling 
PI3K, Jaks, Stat3, Stat5 and Erk molecules are activated as a result of G-CSFR stimulation. At the plasma mem-
brane the receptor tyrosines are phosphorylated by Jaks. The negative regulation of each of the activated pathways is 
restricted to certain sub-cellular compartments. PI3K signaling is regulated at the level of the plasma membrane. In 
early endosomes the lysines of the receptors are ubiquitinated by SOCS3. This acts as a sorting signal for routing to 
late endosomes. The deubiquitinating enzyme DUB2A which can deubiquitinate receptors, most probably acts before 
the receptor routes to the late endosomes. The receptors further route to late endosomes, alternatively via the ER, 
where they are dephosphorylated and the p-Jaks and p-Stat3 molecules are inactivated. In the late endosomes, Erk 
signaling in regulated. The receptors are finally degraded in lysosomes. Although p-Stat5 inactivation depends on the 
ubiquitination of G-CSFR, it is unclear whether p-Stat5 is also inactivated by degradation. 
Figure 2
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5.1.3  Spatio-temporal control of G-CSfR signal down modulation
Attenuation of different signaling pathways occurs in different cellular compartments. While 
Stat3, Stat5 and Erk activation is prolonged in cells expressing the lysine-less K5R receptor 
as compared to wild type controls, the activation of PKB is not prolonged [21]. The K5R-G-
CSFR does route to early endosomes upon stimulation with G-CSF but fails to route to late 
endosomes/ lysosomes. 
The mutant lacking the internalization motif, the ∆749-769 G-CSFR shows prolonged 
Stat3, Stat5, Erk and PKB activation. ∆749-769 G-CSFR mutant is defective in internalization 
and differs from K5R only in prolonged PKB activation. This suggests that the down regula-
tion of PI3K pathway occurs mostly at the plasma membrane. Dephosphorylation of PIP3 
occurs via the  phosphatase PTEN [22]. A small fraction of PTEN is located at the plasma 
membrane and this fraction dephosphorylates PIP3 [23]. The control of p-Erk, p-Stat3 and 
p-Stat5 mediated signaling probably occurs at the level of early endosomes or further down-
stream in the routing cascade (Figure 2). 
The basal levels of both Stat3 and Stat5 activation are higher in cells expressing the 
∆715-G-CSFR as compared to wt-G-CSFR [24]. In luciferase assays, Stat3 activation was 
found to be sensitive to inhibition by SOCS3 [25], while Stat5 activation was found to be 
insensitive to inhibition by SOCS3 in ∆715-G-CSFR expressing cells as compared to those 
expressing the full length G-CSFR [25]. The ∆715-G-CSFR lacks the Y729 residue required 
for recruitment of SOCS3. SOCS3 via ubiquitination of the most membrane proximal lysine 
(K632) of G-CSFR brings about the routing of receptors from early endosomes to lysosomes. 
This suggests that SOCS3 mediated ubiquitination of K632 of G-CSFR is a key step for Stat5 
down regulation, because failure to recruit SOCS3 in case of ∆715-G-CSFR renders it in-
sensitive to inhibition by SOCS3. Stat3 activation appears to be in part regulated by other 
pathways, specifically those that directly interfere with JAK kinase activity.
The pErk signaling of the G-CSFR may continue even after the G-CSFR reaches late 
endosomes, as suggested in the case of EGFR signaling [26]. Interestingly lipid raft adaptor 
p18 which binds to the p14-MP1 complex provides a scaffolding surface for MAPK signaling 
complex on late endosomes [26-27].
Ptp1b dephosphorylates tyrosines of G-CSFR including Y729 which is critical for SOCS3 
binding. Thus Ptp1b via dephosphorylation of Y729 of the G-CSFR may block the SOCS3 
mediated ubiquitination of lysines of the receptor. This in turn may enhance the receptors 
routing via the ER where they are dephosphorylated. Termination of Jak2 and Stat3 signaling 
might take place primarily at the ER. This alternative routing pathway where receptors pass 
the ER on their way to the lysosomes may explain the differential regulation of signaling. 
While Stat5 signal attenuation primarily depends on the lysosomal degradation of the G-
CSFR, Stat3 signal attenuation occurs by dephosphorylation of tyrosines which act as dock-
ing sites for Stat3. Hence, whereas Stat5 signal attenuation depends on SOCS3, Stat3 signal 
attenuation may be regulated by Ptp1b and the kinase inhibitory region of SOCS3 which 
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directly interacts with JAK kinases, independent of docking to the critical tyrosine (Y729) of 
G-CSFR (Figure 3). 
5.1.4  Redox signaling in the context of G-CSfR
Ptp1b is highly sensitive to ROS-mediated inactivation. In case of the G-CSFR, Ptp1b de-
phosphorylates the C-terminal tyrosine of Prdx4. Loss of Ptp1b results in increased phos-
phorylation of Prdx4. No formal evidence yet exists for the regulation of activity of Prdx4 by 
post-translational modifications. The tyrosine of Prdx4 which was found to be phosphory-
lated is also conserved in Prdx1. Recently, a new method for post translational regulation of 
Prdx1 has been described, wherein; Prdx1 was shown to undergo tyrosine phosphorylation 
mediated inactivation upon stimulation with PDGF/ EGF [28]. Prdx2 however was shown 
to be inactivated by oxidation of cysteines and not by phosphorylation. The inactivation of 
Prdx1 led to accumulation of ROS levels in cells. By analogy to Prdx1 it can be envisaged that 
activity of Prdx4 could also be regulated by phosphorylation. Ptp1b could reactivate Prdx4 by 
dephosphorylation of the C-terminal tyrosine of Prdx4. 
After binding of a ligand to its receptor, ROS may be produced in millimolar amounts. 
The current hypothesis is that ROS are produced by the local NADPH oxidase machinery 
and that they locally act on downstream signaling cascades. G-CSFR-induced ROS pro-
duction occurs via the activation of the Lyn-PI3K-PKB pathways, which not only leads to 
activation of p47phox by phosphorylation but also its recruitment to the plasma membrane, 
thereby activating the NADPH oxidase [29]. The levels of ROS produced are higher in 32D 
cells and primary bone marrow cells expressing the ∆715-G-CSFR mutant as compared to 
those expressing the wild type receptor [29]. The inability of ∆715-G-CSFR to undergo rapid 
endocytosis limits its ability to interact with the negative regulatory molecules like Ptp1b and 
Prdx4. This leads to prolonged signaling as well as increased ROS levels in cells expressing 
the ∆715-G-CSFR.
Currently, one of the best documented examples for cytokine responses locally controlled 
by ROS comes from the IL-1 receptor. Upon stimulation with IL-1, assembly of the Nox2 
complex and subsequent ROS production was shown to occur in the early endosome com-
partment [30]. Nox4 was also found to be involved in ROS production and further activation 
of downstream signaling via insulin receptor mainly by inhibition of Ptp1b activity [31-32]. 
In another recent study, it was shown that activation of IL-4 signaling led to generation of 
ROS via PI3K mediated activation of Nox1 and Nox5l [33]. Notably, the ROS produced by 
activation of IL-4 was shown to oxidize and thereby inactivate Ptp1b [33]. 
Based on the above mentioned examples, local production of ROS upon G-CSFR activa-
tion seems likely. Considering the fact that two redox sensitive proteins involved in negative 
regulation of G-CSFR signaling are localised at the ER, the ER appears to be the major site 
of redox-controlled signaling in case of G-CSFR. Whether ROS production upon G-CSFR 
activation occurs at the ER by the local Nox4 complex remains unknown. Based on the
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figure 3: down regulation of G-CSf signaling by SOCS3 and Ptp1b
Inhibition of Stat5 activity is dependent primarily on the recruitment of SOCS3 to tyrosine (Y729) whereby it brings 
about ubiquitination of lysine (K632). Ubiquitination of K632 leads to lysosomal routing of G-CSFRs. Inhibition of 
Stat3 activity is partly dependent on the phosphatase Ptp1b and partly on SOCS3 mediated inhibition of Jaks via the 
KIR of SOCS3. Inhibition of Jaks leads to a block in phosphorylation of tyrosines of G-CSFR and a block in recruit-
ment of Stat3 molecules to the phosphorylated tyrosines. 
findings that the ∆715-G-CSFR produces higher levels of ROS although it does not route to 
the ER, the possibility of another ROS producing complex activated upon stimulation with 
G-CSF at the plasma membrane cannot be ruled out. Whether Prdx4 indeed reduces ROS 
levels in the ER and reactivates Ptp1b requires further investigation. The lack of highly sensi-
tive and reproducible techniques for measuring ROS and phosphatase activities at a local, i.e., 
subcellular level currently remains a major limitation for these studies.
Figure 3
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5.1.5 Role of Prdx4 in leukemogenesis
Peroxiredoxin 4 was identified as fusion partner of AML1 in a myeloid leukemia patient car-
rying t(X;21)(p22;q22) [34]. In Chapter 3 of this thesis, we described that PRDX4 is silenced 
specifically in acute promyelocytic leukemia (APL), characterized by t(15;17), by H3K27-
me3 of the PRDX4 promoter. In Chapter 3 of thesis we also show that PML-RARα binds to 
the transcriptional start site (TSS) of PRDX4. In an attempt to restore PRDX4 expression in 
APLs by de-repressing the PML-RARα complex, we have treated APL cells with (combina-
tions of) pharmacological compounds that included the “de-repressing” agents ATRA, the 
histone deacetylase inhibitor valproic acid and EZH2 inhibitor DZNep, which reduces EZH2 
protein levels and thereby the level of H3K27me3 at transcriptional start sites of certain genes 
[35]. However down regulation of the methyl transferase EZH2 by DZNep, as reported in 
colorectal cancer samples, was not observed in APLs. The reason for this discrepancy is not 
known but may relate to the fact that the majority of APL cells have limited or no ability to 
proliferate in vitro.
As compared to other types of leukemias, APLs are characterized by a relative hyper 
proliferative response to G-CSF [36]. From the AML expression array data of Valk et al [37], 
it can be seen that the expression levels of G-CSFR are higher in APLs as compared to other 
sub-types of AML. Besides, based on our findings that PRDX4 down modulates G-CSFR 
signaling, the hyper proliferative response of APLs to G-CSF might be explained by the loss 
of PRDX4 binding leading to hyper-oxidation of PTP1B resulting in prolonged G-CSFR 
mediated signaling (Chapter 2). 
PML-RARα is known to interact with members of the polycomb repressor complex 
(PRC2) complex which are responsible for H3K27-me3 mediated silencing of loci [38]. Pre-
liminary data from PML-RARα ChIPs shows presence of PML-RARα at the TSS of PRDX4 
locus. The PML-RARα present at the TSS of PRDX4 via its interaction with EZH2, the histone 
methyl transferase of PRC2, could bring about H3K27me3 mediated silencing of PRDX4. 
Retinoic acid receptors (RARs) bind to specific sites in promoters called the retinoic acid 
responsive elements (RAREs). RARs suppress transcription by recruiting corepressor com-
plexes such as SMRT/NCoR/ HDAC [39]. However, considering the fact that the promoter of 
PRDX4 lacks any RAREs, the possibility of repression of PRDX4 expression by recruitment 
of corepressor complexes is unlikely. PML-RARα was also shown to suppress genes indirectly 
by modulation of the activity of transcription factors like Sp1 and bring about suppression 
of the Sp1 target genes [40]. Six Sp1 sites are present within the region of -1kb to +1kb of the 
TSS of PRDX4, to which the PML-RARα fusion protein may bind in a RARE independent 
manner [40]. 
Arsenic trioxide (As2O3) is commonly used for treatment of APLs with PML-RARα 
fusion [41]. In contrast, As2O3 does not affect APLs with PLZF/RARα fusion [42]. 
Degradation of PML/RARα and eradication of leukemia initiating cells can be achieved upon 
treatment of APLs with As2O3. Treatment of APLs with a combination of ATRA and As2O3 
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results in enhanced granulocytic differentiation of APLs and regression of the leukemia [43]. 
Treatment of cells with As2O3also leads to an increase in ROS levels in cells. A result of the 
ROS production is the formation of intermolecular disulphide bonds between either PML 
and / or PML-RARα proteins which bind arsenic directly [44]. The resultant PML and PML-
RARα multimers form nuclear matrix associated nuclear bodies and undergo sumoylation 
and are subsequently degraded [44].  Based on these findings, the treatment of APLs with a 
combination of G-CSF and ATRA could have similar effects. Due to low expression of PRDX4 
in APLs, the levels of ROS produced in response to G-CSF treatment could be higher leading 
to multimerization of PML-RARα. This could result in sumoylation mediated degradation of 
PML-RARα and regression of leukemia. 
New technologies enable the global assessment of changes not only in the expression 
of genes but also the epigenetic changes associated with genes. This allows us to not only 
understand the underlying mechanisms involved in the transformation but also to design 
drugs targeting the key epigenetic modifiers involved in the process. 
5.1.6 Role of Txnip in transformation of myeloid progenitors
In Chapter 4 we describe that the thioredoxin interacting protein (Txnip) is a common virus 
integration site in murine leukemia virus (MLV)-induced leukemia. We found that TXNIP 
expression is upregulated in a subset of human AMLs characterized by t(8;21). The viral 
integrations in the 5’ UTR and 3’ UTR result in increased expression of Txnip, as shown by 
the luciferase assays. Treatment of BaF3/ 32D cells with hydrogen peroxide leads to increased 
expression of Txnip.   
Txnip / Vdup1 is mostly known as a tumor suppressor gene [45-46] whose expression is 
reduced in human breast, colon and lung cancer tissues and also different cell lines derived 
from tumours [53-55]. Our findings however suggest that TXNIP expression is higher as 
compared to control samples in myeloid leukemia. Whether Txnip is directly involved in 
the process of transformation still remains a question. Txnip has been linked to perturbation 
of signaling pathways, which might provide indirect evidence for the role of Txnip in trans-
formation. Txnip has been shown to be a stress response gene which is activated in response 
to ROS, ultraviolet (UV) light, γ-ray exposure and under conditions of high density culture 
and heat shock treatment [47-48]. Interaction of Txnip with Trx might block the transcrip-
tion factor activating ability of Trx [49-50]. Trx interacts with apoptosis signaling kinase 1 
(Ask1) and promotes ubiquitination and degradation of Ask1 [51-52]. Over-expression of 
Txnip leads to inhibition of Trx activity and thereby increased Ask1 activation [9]. Ask1 is a 
MAPKKK and plays a key role in cytokine induced or oxidative stress induced activation of 
JNK and p38 pathways [53]. 
Thioredoxin is essential for reactivation of peroxiredoxins [47]. Inhibition of thioredoxin 
thereby also leads to increased intracellular ROS levels [54]. Txnip might execute its function 
via increased ROS levels leading to inhibition of PTPs. Inhibition of PTPs will result in pro-
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longed/ increased signaling in cells. High amounts of ROS induce damage to DNA, proteins 
and lipids. The damaged DNA that escapes the DNA replication machinery can contribute 
to the development of cancer. High levels of ROS are known to induce apoptosis in cells by 
targeting the anti-apoptotic Bcl family members for proteasomal degradation. Overexpres-
sion of anti-apoptotic Bcl-2 family members like Bcl-2 and Bcl-XL protects cells from ROS 
induced apoptosis [55-56]. However whether the apoptotic stimuli induced by ROS can be 
counteracted by the anti-apoptotic Bcl proteins remains unknown. More studies have to be 
performed in order to shed light on the exact role of this protein in transformation.
5.2 PERSPECTIvE 
Scavenging peroxide in cancer cells can lead to a block in proliferation due to inhibition of 
growth factor signaling. However this process might prove to be complicated due to existent 
redundancy in pathways resulting in tumor growth. Many inhibitors of antioxidants are cur-
rently being used as chemotherapeutic agents with the rationale that accumulation of ROS 
will result in apoptosis in cells. However these approaches do not target specific molecules. 
It is clear that there exists a complex correlation between cellular signaling pathways and 
cellular redox status. Although the role of redox regulation in cellular signaling is evident, its 
importance for many cellular functions remains unknown. It is important to study the role 
of redox regulation and the underlying molecular mechanisms in cells in order to be able to 
target the key players involved in these pathways for therapeutic purposes. 
5.3 SuMMaRy
During the last few years more evidence has gathered for the role of ROS as second messen-
gers in signaling. Although it has been shown that activation of receptors leads to production 
of reactive oxygen species, the exact targets of ROS have not been identified.
Chapter 1 of this thesis focuses on G-CSFR signaling. Activation of downstream signaling 
pathways which either activate signaling or switch off signaling have been described in detail. 
Also, the endocytotic pathway taken by the G-CSFR has been described. Special attention 
has been paid to the role of ROS in controlling signaling. ROS are produced locally. However 
they are highly unstable and reactive molecules which can diffuse easily throughout the cell. 
How do these molecules which are produced locally execute their function on different sig-
naling molecules? Several antioxidant proteins with distinct sub-cellular localizations play an 
important role not only in limiting the amount of ROS but also in recycling of phosphatases 
which are inactivated due to ROS.  
Chapter 2 describes the role of an antioxidant protein, Prdx4 which was found to nega-
tively regulate signaling via the G-CSFR. Although, Prdx4 is predominantly localized in the 
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endoplasmic reticulum (ER) it was found to interact with internalised G-CSFR vesicles 
indicating that G-CSFR vesicles pass the ER on their way to the lysosomes. The C-terminal 
domain of the G-CSFR was found to be critical for interaction with Prdx4. Negative regula-
tion of G-CSF mediated proliferation and signaling by Prdx4 in myeloid progenitor cells was 
strictly dependent on the presence of catalytic cysteines in the active site of Prdx4. Loss of 
Prdx4 expression led to increased colony formation in myeloid progenitor cells as compared 
to wild type controls.  Loss of Prdx4 also led to increased Stat3 levels as compared to wild type 
control MEFs.
Chapter 2 also reports that another ER resident protein tyrosine phosphatase, Ptp1b 
negatively regulates proliferation via G-CSF in myeloid progenitor cells. Loss of Ptp1b led 
to prolonged phosphorylation of tyrosines of the G-CSFR and also increased activation 
of Stat3 and Jak2 as compared to Ptp1b reconstituted MEFs. Ptp1b is also responsible for 
dephosphorylation-mediated reactivation of Prdx4. The activated Prdx4 then could reduce 
ROS and reactivate Ptp1b completing a positive feed back loop for down regulation of G-CSF 
signaling.
In Chapter 3 it is shown that PRDX4 expression is very low or absent in acute promyelo-
cytic leukemia (APL) patients characterised by the chromosomal translocation t(15;17). Also 
the proteins levels of PRDX4 are very low in APLs as compared to other leukemias. The low 
expression of PRDX4 is only associated with APL and not promyelocytes, the cells from which 
this leukemia is derived, indicating that this is a leukemia-related phenomenon. Although a 
bivalent chromatin methylation mark is present at the TSS of PRDX4, H3K27me3 is the 
dominant repressive mark. No aberrant methylation of CpG islands in the PRDX4 promoter 
region of was detected in APL. The fusion product, PML-RARα resulting from the t(15;17) 
was found to be associated with the promoter of PRDX4. PML-RARα is known to recruit 
the PRC2 complex, responsible for H3K27-me3. This could explain the correlation between 
PML-RARα and H3K27-me3 presence at the TSS of PRDX4 and silencing of PRDX4 in APLs.
In Chapter 4 it was shown that Txnip, the gene encoding a protein that is also involved 
in oxidative stress mediated signaling, is a common virus integration site in murine myeloid 
leukemia induced by murine leukemia virus. Ectopic expression of Txnip in myeloid pro-
genitor cells, leads to decreased proliferation of these cells. Furthermore, the expression (both 
mRNA and protein) of TXNIP was found to be higher in certain AML samples, particularly 
those carrying the t(8;21). No mutations in TXNIP were reported in AMLs. Combining the 
murine and human AML data, may suggest that abnormal expression of Txnip is associated 
with AML.
Finally, in Chapter 5 the results reported in this thesis have been summarized and dis-
cussed in a broader perspective.
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In de voorbije jaren is bekend geworden dat zuurstof radicalen (reactive oxygen species, 
afgekort als ROS) een rol spelen bij de intracellulaire signaalafgifte (signaaltransductie) door 
groeifactorreceptoren. Hoewel het nu vast staat dat activering van groeifactorreceptoren leidt 
tot verhoogde aanmaak van ROS en veranderingen in de signaalfunctie, zijn de onderliggende 
werkingsmechanismen nog grotendeels onbekend.
Hoofdstuk 1 van dit proefschrift richt zich op de belangrijkste principes van G-CSF 
receptor (G-CSFR) signalering. Mechanismen die verantwoordelijk worden geacht voor de 
activering en uitschakeling van de aan de G-CSFR gekoppelde signaalwegen worden hier 
ingeleid. Ook wordt het principe van G-CSFR endocytose beschreven. Speciale aandacht is 
gericht op de regulerende rol van ROS in signaaltransductie. Het wordt steeds duidelijker 
dat ROS zeer lokaal in de cel worden geproduceerd. ROS moleculen zijn echter zeer instabiel 
en kunnen zich gemakkelijk door de hele cel verplaatsen. Een belangrijke vraag is hoe ROS 
moleculen die lokaal worden geproduceerd hun functie op verschillende signaalmoleculen 
uitvoeren. Meerdere antioxidant eiwitten en oxidatiegevoelige fosfatasen, gelokaliseerd 
in verschillende subcellulaire compartimenten zoals het endoplasmatisch reticulum (ER), 
blijken hierbij een belangrijke rol te spelen. 
Hoofdstuk 2 handelt over de remmende werking van het antioxidant eiwit peroxiredoxin-4 
(Prdx4) op de signaalfunctie van G-CSFR. Hoewel Prdx4 voornamelijk in het ER is gelokali-
seerd werd een interactie met de geïnternaliseerde,  in endocytotische blaasjes aanwezige G-
CSFR eiwitten waargenomen, wat duidt op een passage van deze G-CSFR bevattende blaasjes 
langs het ER. Het carboxyl-terminale gedeelte van de G-CSFR bleek essentieel te zijn voor 
de binding met Prdx4. De remmende werking van Prdx4 op de door G-CSF geïnduceerde 
proliferatie van myeloide voorlopercellen bleek strikt afhankelijk van de aanwezigheid van de 
katalytisch actieve cysteine residuen in Prdx4. Verlies van Prdx4 expressie resulteerde in een 
toename van G-CSF geïnduceerde kolonievorming door myeloide voorlopercellen. Verlies 
van Prdx4 expressie leidde ook tot verhoogde activering van het STAT3 eiwit in vergelijking 
tot normale controle cellen.
In Hoofdstuk 2 wordt verder uiteengezet hoe het eiwit tyrosinefosfatase Ptp1b, ook een 
enzym dat zich in het ER bevindt, de door G-CSF geïnduceerde proliferatie van myeloide 
voorlopercellen remt. Verlies van Ptp1b leidde tot een verlengde tyrosinefosforylering van 
de G-CSFR en ook tot verhoogde activiteit van STAT3 en Jak2, in vergelijking tot controle 
cellen. Bovendien werd aangetoond dat Ptp1b verantwoordelijk is voor de defosforylering 
van Prdx4, wat mogelijk een verhogend effect heeft op de activiteit van Prdx4. De resultaten 
passen in een model waarin het actieve Prdx4 lokaal, d.w.z. nabij het ER, de hoeveelheid ROS 
verlaagt waardoor het oxidatie gevoelige Ptp1b actief blijft.
In Hoofdstuk 3 wordt beschreven dat de expressie van PRDX4 transcripten zeer laag of 
zelfs afwezig is in acute promyelocyten leukemie (APL) cellen, gekenmerkt door de chromo-
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soom translocatie t(15;17). Ook op eiwitniveau is de expressie van PRDX4 in APL cellen zeer 
laag vergeleken met andere typen leukemiecellen. De lage expressie van PRDX4 werd niet in 
normale, d.w.z. niet leukemische promyelocyten gezien, wat aangeeft dat verlaagde PRDX4 
expressie een leukemie gerelateerd fenomeen is. Hoewel er een zogenaamde bivalente histon 
methylering markering aanwezig is op de transcriptie start site (TSS) van PRDX4, overheerst 
histon H3K27 tri-methylering (me3), leidend tot onderdrukking van PRDX4 genexpressie. 
Er werd geen afwijkend DNA methyleringspatroon van CpG eilanden in de PRDX4 promoter 
regio waargenomen. Het PML-RARα fusie-eiwit, ontstaan door de t(15;17) chromosoomfu-
sie, bleek te binden aan de PRDX4 promoter. Van PML-RARα is bekend dat het aan het 
PRC2 complex kan binden dat verantwoordelijk is voor de trimethylering van H3K27. Dit 
vormt de mogelijke verklaring voor de betrokkenheid van PML-RARα bij de vorming van 
H3K27-me3 op de TSS van PRDX4, leidend tot de onderdrukte expressie van het PRDX4 
eiwit in APL.
In Hoofdstuk 4 wordt getoond dat Txnip, het gen dat codeert voor thioredoxin-interacting 
protein (Txnip), een eiwit betrokken bij ROS gereguleerde signaalprocessen een zogenaamde 
common virus integration site (CIS) is in door retrovirus veroorzaakte leukemie bij de muis. 
Ectopische expressie van Txnip in myeloide voorlopercellen leidde tot verlaagde proliferatie 
van deze cellen. Bovendien was de expressie (zowel op mRNA als op eiwitniveau) van Txnip 
verhoogd in humane AML cellen, in het bijzonder in AML met de chromosoom translocatie 
t(8;21). Er werden geen mutaties in het TXNIP gen gevonden bij AML patiënten. De gecom-
bineerde resultaten van de studies bij de muis en in humane AML suggereren dat afwijkende 
expressie van TXNIP een rol kan spelen in AML, maar welke redox-gevoelige mechanismen 
hierbij betrokken zijn is nog onduidelijk.
In Hoofdstuk 5, tenslotte, worden de resultaten beschreven in dit proefschrift samengevat 
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abbREvIaTIONS
aML Acute Myeloid Leukemia
aPL Acute Promyelocytic Leukemia 
ask1 Apoptosis signaling Kinase 1
CaT Catalase 
CfP Cyan Flourescent protein
ChIP Chromatin Immunoprecipitations
CIS Common Integration Site
CLSM Confocal Laser Scanning Microscopy
CML Chronic Myeloid Leukemia
CSf3R Granulocyte colony stimulating factor receptor
dSPs/ duSPs Dual Specificity Phosphatases
dubs de-ubiquitinating enzymes 
dZNep 3-deazaneplanocin A
EEa1 Early Endosome Antigen 1
EEd Embryonic ectoderm development
EGf Epidermal Growth Factor 




ERad ER-associated degradation 
ERGIC Endoplasmic Reticulum Golgi Intermediate Compartment
ESCRT Endosomal sorting complex required for transport
EZh2 Enhancer of zeste homolog 2
fCS Fetal Calf Serum
fISh Flourescent in-situ hybridization
G-CSf  Granulocyte Colony Stimulating Factor
G-CSfR Granulocyte Colony Stimulating Factor Receptor
GfP Green Flourescent protein
GM-CSf  Granulocyte-Macrophage Colony-Stimulating Factor 
GM-CSfR Granulocyte-Macrophage Colony-Stimulating Factor Receptor
GPx Glutathione peroxidise
Gr 1.4 Graffi 1.4
h2O2 Hydrogen Peroxide
h3K27-me3  Trimethylation of lysine 27 of histone 3 
h3K4-me3 Trimethylation of lysine 4 of histone 3 
h3K36-me2 Bimethylation of lysine 36 of histone 3 
Abbreviations




hEK cells  Human embryonic kidney cells
hGfs Hematopoietic growth factors 
hSCs Hematopoietic Stem Cells
IL-R Interleukin Receptor 
Jak Janus Tyrosine Kinase
K Lysine
LTR Long Terminal Repeat
MaPPIT Mammalian Protein Protein Interaction Trap
Mbd Methyl-CpG binding domain protein 
MdS Myelodysplastic Syndrome
MEfs Mouse Embryonic Fibroblasts
MuLv Murine Leukemia Virus





PdGfR Platelet-Derived Growth Factor Receptor  
Ph2 Pleckstrin Homology 2
PI3K Phosphoionositol 3 kinase
PKb Protein kinase B
PLZf Promyelocytic leukemia zinc finger
PML Promyelocytic Leukemia
PRC Polycomb Repressor Complex
Prdx Peroxiredoxin 
PTK Protein Tyrosine Kinase
PTP Protein Tyrosine Phosphatase
Ptp1b Protein Tyrosine Phosphatase 1b
RaR Retinoic Acid Receptor
RaREs Retinoic Acid Responsive Elements
ROS Reactive Oxygen Species
RPTPs Receptor Protein Tyrosine Phosphatases 
S Serine
SCf Stem Cell Factor
SCN Severe Congenital Neutropenia
Sh2 Src Homology 2
ShIP1 SH2 Domain-containing Ionositol Phosphatase 
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ShP1 Src Homology 2 domain phosphatase 1
ShP2 Src Homology 2 domain phosphatase 2
SOCS Suppressor of Cytokine Signaling
SOd Superoxide dismutase 
STaM2 Signal transducing adapter molecule 2
STaT Signal Transducer and Activator of Transcription
SuZ12 Enhancer of zeste homolog 12
T Threonine
t(15;17) Translocation between chromosomes 15 and 17
t(8;21) Translocation between chromosomes 8 and 21
TPO Thrombopoietin Receptor
TPβ Thromboxane A2 receptor 
TRaIL TNF-related apoptosis inducing ligand
TRx/ TxN Thioredoxin 
TSS Transcriptional Start Site
Txnip Thioredoxin interacting protein
uTR Untranslated Region
vdup1 Vitamin D3 upregulated protein 1
vIS Viral Integration Site
wsb WD-repeat domain and SOCS box-containing protein
y Tyrosine
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COLOR SECTION
figure 2. G-CSfR and Prdx4 interaction and co-localization
(a) HeLa cells ectopically expressing WT G-CSFR were growth factor-deprived for 4 hrs. Surface membrane 
G-CSFRs were labelled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx4 antibody, followed by secondary and anti-rabbit Cy3 and anti-
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figure 2. G-CSfR and Prdx4 interaction and co-localization 
(b) Co-localization of endocytosed G-CSFR with Grp94-stained ER and with ERGIC 30 min. after ligand stimula-
tion. Experimental conditions were the same as under B.
figure S3: HeLa cells ectopically expressing wt-G-CSFR were growth factor deprived for 4 hrs. Surface membrane 
G-CSFRs were labeled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx4 and eea1 antibodies followed by secondary anti-goat 488, anti-
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figure S4a: HeLa cells ectopically expressing K5R-G-CSFR were growth factor deprived for 4 hrs. Surface membrane 
G-CSFRs were labeled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx4 antibody followed by secondary and anti-rabbit Cy3 and anti-
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figure S5: HeLa cells ectopically expressing wt-G-CSFR were growth factor deprived for 4 hrs. Surface membrane 
G-CSFRs were labeled with anti-G-CSFR antibody prior to stimulation with G-CSF for different time points. Cells 
were permeabilised, fixed and stained with anti-Prdx2 antibody followed by secondary and anti-rabbit Cy3 and anti-
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figure S6: CLSM showing the co-localization of Prdx4 with markers for various sub-cellular compartments in HekT 
cells. The ER-Golgi-Intermediate Compartment was stained using an antibody against ERGIC, the ER with anti-
calnexin and the Golgi with anti-GM130.
figure S7: (A) CLSM showing routing of G-CSFR-Prdx4 fusion protein towards ER and ERGIC comparable to WT 
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figure 1: Expression of PRDX transcripts in aML and aPL
(a) Graphical representation of expression of PRDX family members in APL patients clustered based on expression 
of ~2000 genes as described [14]. Cluster 12 is exclusively formed by APL patients, as indicated by the red bars indi-
cating the presence of t(15;17). Cluster 11 comprises AML patients with normal karyotype and an underlying NPM1 
mutation. Cluster 13 is formed by AML patients with t(8;21). Histograms represent MAS5-normalized expression 
values.
(C) APLs are not associated with high expression of TRAIL ligand excluding the possibility that low expression of 
PRDX4 could be attributed to high levels of TRAIL
figure 2: Reduced PRdx4 protein levels in aPL  




KP.indd   138 28-2-2011   11:54:31
139
ChaPTER 4
figure 2. TXNIP levels in human aML samples
(a) Level of TXNIP mRNA expression in 285 human AML samples. The 16 clusters with molecular characteristics 
in a cohort of 285 AML patients have been published [247] and are depicted on the X-axis. Molecular characteristics 
associated with the clusters are: cluster 1: t(11q23), 2: FLT3-ITD, 3: FLT3ITD, 4: CEBPα mutations, 6: FLT3-ITD, 
9: inv(16), 10: Evi-1, 12: t(15;17), 13: t(8;21), 15: CEBPα mutations, 16: t(11q23). TXNIP mRNA expression was 
found significantly lower (as indicated by *) or higher (**) by SAM analyses in clusters of leukemia. Probe sets of 
TXNIP were considered to be differentially expressed when Fold Change was over 1.5 or under 0.67, score was over 
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